Document:

License Agreement

 Exhibit 10.16 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

LICENSE AGREEMENT 
 BETWEEN 
 GENOMATICA, INC. 

AND 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 
 FOR 
 [...***...] 

  

			
		  	***Confidential Treatment Requested

 TABLE OF CONTENTS 

 

							
	Article 1:	  	Definitions	  	 	3	  
			
	Article 2:	  	Grant	  	 	6	  
			
	Article 3:	  	Considerations	  	 	8	  
			
	Article 4:	  	Reports, Records and Payments	  	 	11	  
			
	Article 5:	  	Patent Matters	  	 	14	  
			
	Article 6:	  	Governmental Matters	  	 	16	  
			
	Article 7:	  	Termination of Agreement	  	 	16	  
			
	Article 8:	  	Limited Warranty and Indemnification	  	 	17	  
			
	Article 9:	  	Use of Names and Trademarks	  	 	19	  
			
	Article 10:	  	Miscellaneous Provisions	  	 	19	  
			
	Exhibit A:	  	Stock Purchase Agreement and Restated Articles of Incorporation	  			
			
	Exhibit B:	  	Assignment of [...***...] Invention	  			

  

			
		  	***Confidential Treatment Requested

 LICENSE AGREEMENT 

This agreement (“Agreement”) is made by and between Genomatica, Inc., a California corporation having an address at 5405
Morehouse Drive, Suite 210, San Diego, CA 92121 (“LICENSEE”) and The Regents Of The University Of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200
(“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Technology Transfer & Intellectual Property Services, Mail-code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910
(“UCSD”). 
 This Agreement is effective on the date of the last signature (“Effective Date”). 

RECITALS 

WHEREAS, the parties have previously entered into a license agreement with an effective date of July 8, 1999 (UC control number
2000-03-0001) (the “Prior Agreement”) whereby University licensed certain rights under certain of the Inventions (defined below) to LICENSEE; 
 WHEREAS, this Prior Agreement shall terminate on the Effective Date of this Agreement; 
 WHEREAS, the inventions disclosed in UCSD Case Docket No. [...***...] were made by [...***...] (hereinafter, the “[...***...] Inventor”) and are covered by Patent Rights as
defined below [...***...]; 
 [...***...] 

  

			
	1.	  	  
 ***Confidential Treatment
Requested

 [...***...] 
 WHEREAS, the [...***...] Inventors are employees of UCSD, and they are obligated to assign all of their right, title and interest in the [...***...] Invention to UNIVERSITY; [...***...];

 WHEREAS, UNIVERSITY is desirous that the Inventions be developed and utilized to the fullest possible extent so that their
benefits can be enjoyed by the general public; 
 WHEREAS, LICENSEE is desirous of obtaining certain rights from UNIVERSITY for
commercial development, use, and sale of the Inventions, and the UNIVERSITY is willing to grant such rights; and 
 WHEREAS,
LICENSEE understands that UNIVERSITY may publish or otherwise disseminate information concerning the Inventions and Technology (as defined below) at any time and that LICENSEE is paying consideration hereunder [...***...]. 

  

			
	2.	  	  
 ***Confidential Treatment
Requested

 NOW, THEREFORE, the parties agree as follows: 

ARTICLE 1 

DEFINITIONS 
 The terms, as defined herein, shall have the same meanings in both their singular and plural forms. 
 1.1 “Affiliate” means any corporation or other business entity in which LICENSEE owns or controls, directly or indirectly, at least fifty percent (50%) of the outstanding stock or
other voting rights entitled to elect directors, or in which LICENSEE is owned or controlled directly or indirectly by at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors; but in any country
where the local law does not permit foreign equity participation of at least fifty percent (50%), then an “Affiliate” includes any company in which LICENSEE owns or controls or is owned or controlled by, directly or indirectly, the maximum
percentage of outstanding stock or voting rights permitted by local law. 
 1.2 “Sublicensee” means a third
party to whom LICENSEE grants a sublicense of certain rights granted to LICENSEE under this Agreement, excluding any distributor, Third Party Partner or any end user of any Model Licensed Product. 

1.3 “Field” means [...***...]. 
 1.4 “Territory” means worldwide. 
 1.5 “Term”
means the period of time beginning on the Effective Date and ending on the later of (i) the expiration date of the longest-lived Patent Rights; or (ii) the twenty-first (21st) anniversary of Effective Date, unless terminated earlier
pursuant to Paragraph 7 hereof. 
 1.6 “Inventions” means any and all or any combination of
[...***...] Inventions, as context may require. 
 1.7 “[...***...] Patent Rights” means
[...***...] disclosing and claiming the [...***...] Invention, filed by [...***...] Inventor; and continuing applications thereof including divisions, substitutions, and continuations-in-part (but only to extent the claims thereof
are enabled by disclosure of the parent application); any patents issuing on said applications including reissues, reexaminations and extensions; and any corresponding foreign applications or patents. 

1.8 [...***...] 

  

			
	3.	  	  
 ***Confidential Treatment
Requested

 [...***...] 
 1.9 [...***...] 
 1.10 [...***...] 

1.11 [...***...] 
 1.12 [...***...] 
 1.13 [...***...] 

  

			
	4.	  	  
 ***Confidential Treatment
Requested

 1.14 “Patent Rights” means [...***...] as context may require.

 1.15 “Technology” means the written technical information, data, knowledge, algorithms, computer programs,
and/or software relating to any Invention, Licensed Product or Licensed Method which the Inventors or UNIVERSITY provide to LICENSEE prior to or as of the Effective Date. 
 1.16 “Sponsor Rights” means all the applicable provisions of any license to the United States Government executed by UNIVERSITY and the overriding obligations to the Federal Government
under 35 U.S.C. §§ 200-212 and applicable governmental implementing regulations. 
 1.17 “Licensed
Method” means any method that uses Technology, or is covered by any pending or issued and unexpired claim within the Patent Rights the use of which would constitute, but for the license granted to LICENSEE under this Agreement, an infringement
of any pending or issued and unexpired claim within Patent Rights. 
 1.18 “Licensed Product” means any
composition or product that uses Technology, or is covered by any pending or issued and unexpired claim within the Patent Rights, or that is produced by the Licensed Method, or the manufacture, use, sale, offer for sale, or importation of which
would constitute, but for the license granted to LICENSEE by UNIVERSITY herein, an infringement of any pending or issued and unexpired claim within the Patent Rights. 
 1.19 “Model Licensed Product” means any Standard Model Licensed Product, Modified Licensed Product and/or New Model Licensed Product. 

1.20 “Standard Model Licensed Product” means a Licensed Product that is [...***...]. 

1.21 “Modified Model Licensed Product” means a Licensed Product that is [...***...]. 

1.22 “New Model Licensed Product” means a Licensed Product that is [...***...]. 

1.23 “Net Sales” means the total of the gross invoice prices of Licensed Products sold by LICENSEE, [...***...]
less the sum of the following actual and customary deductions where applicable and separately listed: cash, trade, or quantity discounts; sales, use, tariff, import/export duties or other excise taxes imposed on particular sales (except for
value-added and income taxes imposed on the sales of Licensed Products in foreign countries); transportation charges; or credits to customers because of 

  

			
	5.	  	  
 ***Confidential Treatment
Requested

 
rejections or returns. [...***...]. In the event that LICENSEE or any of its Affiliates sells Licensed Products through one or more distributors, Net Sales will include amounts received by
LICENSEE or its Affiliates for the sale of such Licensed Products to such distributors, but will not include any amounts received by such distributors for the sale of Licensed Products. 

1.24 “Consideration” means any consideration received by LICENSEE, including license fees, milestone payments, royalties
and stock premiums, [...***...]. 
 1.25 “Third Party Partner” means any entity that contracts with
LICENSEE for the purpose of LICENSEE developing for and delivering to such entity any deliverable (each, a “Deliverable”) that is either [...***...]. 
 1.26 “Patent Costs” means all out-of-pocket expenses for the preparation, filing, prosecution, and maintenance of all United States and foreign patents included in Patent Rights. Patent
Costs shall also include reasonable out-of-pocket expenses for patentability opinions, inventorship determination, preparation and prosecution of patent application, re-examination, re-issue, interference, and opposition activities related to
patents or applications in Patent Rights. 
 1.27 “Combination Product” means any product which is a Model
Licensed Product and contains other product(s) or product component(s) that (i) does not use Invention, Technology or Patent Rights; (ii) the sale, use or import by itself does not contribute to the infringement of Patent Rights;
(iii) can be sold separately by LICENSEE, its Sublicensees or an Affiliate; and (iv) enhances the market price of the final product(s) sold, used or imported by LICENSEE, its Sublicensee, or an Affiliate. 

ARTICLE 2 

GRANTS 

2.1 Patent License. Subject to the limitations set forth in this Agreement and Sponsor’s Rights, UNIVERSITY hereby grants to
LICENSEE and its Affiliates who agree in writing to be bound by this Agreement, and LICENSEE hereby accepts (on behalf of itself and its Affiliates), a license under UNIVERSITY’S interest in Patent Rights [...***...] 

  

			
	6.	  	  
 ***Confidential Treatment
Requested

 
[...***...] to make, have made, use, sell, offer for sale, and import Licensed Products and to practice Licensed Methods and to use Technology and to copy, distribute, modify and create
derivative works from the copyrighted material, if any, included in the Technology, in the Field within the Territory and during the Term. 
 2.2 The license granted herein is exclusive for UNIVERSITY’S Patent Rights and any copyrights included within the Technology, and UNIVERSITY shall not grant to third parties a further license
under Patent Rights or such copyrights in the Field, within the Territory and during the Term. 
 2.3 Sublicense.

 (a) The license granted in Paragraph 2.1 includes the right of LICENSEE to grant sublicenses to third parties during
the Term [...***...]. 
 (b) With respect to sublicenses granted pursuant to Paragraph 2.2 LICENSEE shall:

 (1) [...***...]; 
 (2) to the extent applicable, include all of the rights of and obligations due to UNIVERSITY (and, if applicable, the Sponsor’s Rights) and contained in this Agreement; 

(3) promptly provide UNIVERSITY with a copy of each sublicense issued; and 

(4) collect and guarantee payment of all payments due, directly or indirectly, to UNIVERSITY from Sublicensees and summarize and deliver
all reports due, directly or indirectly, to UNIVERSITY from Sublicensees. 
 (c) Upon termination of this Agreement for
any reason, UNIVERSITY, at its reasonable discretion, shall determine whether LICENSEE shall cancel or assign to UNIVERSITY any and all sublicenses; provided, however, that LICENSEE may submit a proposed sublicense to UNIVERSITY in advance for
UNIVERSITY’s prior approval, such approval not to be unreasonably withheld or delayed (i.e. UNIVERSITY will respond within forty-five (45) days after receipt of such proposal from LICENSEE), and if UNIVERSITY approves such sublicense, then
such sublicense shall also become a direct license between the Sublicensee and UNIVERSITY upon termination of this Agreement for any reason, provided that such Sublicensee is not the cause of the termination of this Agreement. 

2.4 Reservation of Rights. UNIVERSITY reserves the right to: 

(a) use the Inventions, Technology (including copyrights subsisting therein) and Patent Rights for educational and research
purposes; and 

  

			
	7.	  	  
 ***Confidential Treatment
Requested

 (b) publish or otherwise disseminate any information about the Invention and
Technology at any time, provided that any such publication or dissemination shall not inhibit the ability of Inventions to be patented; and 
 (c) allow other nonprofit institutions to use Invention, Technology (including copyrights subsisting therein) and Patent Rights for educational and non-commercial research purposes in their
facilities. 
 ARTICLE 3 
 CONSIDERATIONS 
 3.1 Fees and Royalties. The parties hereto
understand that the fees and royalties payable by LICENSEE to UNIVERSITY under this Agreement are partial considerations for the license granted herein to LICENSEE under Technology and Patent Rights. LICENSEE shall pay UNIVERSITY: 

(a) a license issue fee of : 
 (i) [...***...] upon execution of this Agreement; and] 
 (ii)
[...***...] shares of LICENSEE’S Series A-1 Preferred Stock (having the same antidilution protection as the Series A Preferred Stock authorized in the Restated Articles of Incorporation of LICENSEE, a copy of which is
attached to this Agreement as Exhibit A). Such Series A-1 Preferred Stock shall be issued to and delivered to UNIVERSITY within thirty (30) days after written notice of approval of equity acceptance from the Office of the President of
the University of California. In the event that such an approval is not granted, this Agreement shall remain in effect and LICENSEE and UCSD shall renegotiate in good faith for a substitution of similar value for consideration. 

(b) milestone payments within [...***...] after the occurrence of the following events in the amounts set forth opposite the
applicable event in the table below: 
  

			
	 Milestone Payment Amount
	  	Milestone Event
	 (i) [...***...]
	  	[...***...]
		
	 (ii) [...***...]
	  	[...***...]

  

			
	8.	  	  
 ***Confidential Treatment
Requested

 (c) an earned royalty: 

 

	 	(I)	on Net Sales by LICENSEE and/or its Affiliates: 

  

	 	(i)	[...***...] for Standard Model Licensed Products; 

  

	 	(ii)	[...***...] for Modified Model Licensed Products; and 

  

	 	(iii)	[...***...] for New Model Licensed Products. 

 [...***...] 
 No multiple royalties shall be payable because any Model Licensed Product or
Deliverable, or its manufacture, use or sale is covered by more than one claim or patent or patent application within the Patent Rights. 
 (d) [...***...] 

  

			
	9.	  	  
 ***Confidential Treatment
Requested

 [...***...]. 
 (e) [...***...]. 
 (f) [...***...]. 

All fees and royalty payments to be paid by LICENSEE hereunder shall be paid by LICENSEE pursuant to Paragraph 4.3 and shall be delivered
by LICENSEE to UNIVERSITY as noted in Paragraph 10.1. 
 3.2 Patent Costs. LICENSEE shall reimburse UNIVERSITY all past
(prior to the Effective Date) and unreimbursed and future (on or after the Effective Date) Patent Costs [...***...] following receipt by LICENSEE of an itemized invoice from UNIVERSITY. 

3.3 Due Diligence. 
 (a) LICENSEE shall: 
 (1) diligently proceed with the development,
manufacture and sale of Licensed Products; 
 (2) annually spend not less than [...***...] for the development of
Licensed Products during the first [...***...] of this Agreement; provided, however, that once LICENSEE has spent [...***...] or more developing Licensed Products, it shall be deemed to have satisfied its obligations under this Paragraph
3.3(a)(2). LICENSEE may, at its sole option, fund the research of any one of the Inventors and credit the amount of such funding actually paid to UCSD against its obligation under this paragraph; 

(3) market Licensed Products in the United States [...***...] of receiving regulatory approval to market such Licensed Products;

  

			
	10.	  	  
 ***Confidential Treatment
Requested

 (4) reasonably fill the market demand for Licensed Products following commencement of
marketing at any time during the term of this Agreement; and 
 (5) obtain all necessary governmental approvals for the
manufacture, use and sale of Licensed Products. 
 (b) If LICENSEE fails to perform any of its obligations specified in
Paragraphs 3.3(a)(1)-(5), then UNIVERSITY shall have the right and option to either terminate this Agreement or change LICENSEE’s exclusive license to nonexclusive license. This right, if exercised by UNIVERSITY, supersedes the rights granted
in Article 2. 
 ARTICLE 4 
 REPORTS, RECORDS AND PAYMENTS 
 4.1 Reports. 

(a) Progress Reports. 
 (1) Beginning January 1, 2002 and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall submit to UNIVERSITY once each calendar year a progress report
covering LICENSEE’s (and Affiliate’s and Sublicensee’s) activities to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such reports shall include a summary of work completed;
summary of work in progress; current schedule of anticipated events or milestones; market plans for introduction of Licensed Products; and summary of resources (dollar value) spent in the reporting period. 

(2) LICENSEE shall also report to UNIVERSITY, in its immediately subsequent progress report, the date of first commercial sale of a
Licensed Product in each country. 
 (b) Royalty Reports. After the first commercial sale of a Licensed Product anywhere
in the world, LICENSEE shall submit to UNIVERSITY quarterly royalty reports on or before each February 28, May 31, August 31 and November 30 of each year. Each royalty report shall cover LICENSEE’s (and each
Affiliate’s and Sublicensee’s) most recently completed calendar quarter and shall show: 
 (1) the gross sales,
deductions as provided in Paragraph 1.23, and Net Sales during the most recently completed calendar quarter and the royalties, in US dollars, payable with respect thereto; 

 

	 	(2)	the number of each type of Licensed Product sold; 

  

	 	(2)	Sublicense fees and royalties; 

  

			
	11.	  	

	 	(3)	Consideration for Deliverables received during the most recently completed calendar quarter in US dollars, payable with respect thereto; 

 

	 	(4)	the method used to calculate the royalties; and 

  

	 	(5)	the exchange rates used. 

 If no
sales of Licensed Products or Deliverables have been made and no sublicense revenues have been received by LICENSEE during any reporting period, LICENSEE shall so report. 
 4.2 Records & Audits. 
 (a) LICENSEE shall
keep, and shall require its Affiliates and Sublicensees to keep, accurate and correct records of all Licensed Products manufactured, used, and sold, Deliverables developed and sold, and sublicense fees received under this Agreement. Such records
shall be retained by LICENSEE for at least five (5) years following a given reporting period. 
 (b) All records
shall be available during normal business hours for inspection at the expense of UNIVERSITY by UNIVERSITY’s Internal Audit Department or by a Certified Public Accountant selected by UNIVERSITY and in compliance with the other terms of this
Agreement for the sole purpose of verifying reports and payments. Such inspector shall not disclose to UNIVERSITY any information other than information relating to the accuracy of reports and payments made under this Agreement or other compliance
issues. In the event that any such inspection shows an under reporting and underpayment in excess of [...***...] for any twelve (12) month period, then LICENSEE shall pay the cost of the audit as well as any additional sum that would have
been payable to UNIVERSITY had the LICENSEE reported correctly, plus an interest charge at a rate of [...***...] per year. Such interest shall be calculated from the date the correct payment was due to UNIVERSITY up to the date when such
payment is actually made by LICENSEE. For underpayment not in excess of [...***...] for any twelve (12) month period, LICENSEE shall pay the difference within thirty (30) days without interest charge or inspection cost. If the
inspection shows any overpayment by LICENSEE, UNIVERSITY shall promptly credit such amount to any royalties that may be owed by LICENSEE to UNIVERSITY in the future. 
 4.3 Payments. 
 (a) All fees and royalties due
UNIVERSITY shall be paid in United States dollars and all checks shall be made payable to “The Regents of the University of California”, referencing UNIVERSITY’S taxpayer identification number, 95-6006144. When Licensed Products are
sold in currencies other than United States dollars, LICENSEE shall first determine the earned royalty in the currency of the country in which Licensed Products were sold and then convert the amount into equivalent United States funds, using the
exchange rate quoted in the Wall Street Journal on the last business day of the applicable reporting period. 

  

			
	12.	  	  
 ***Confidential Treatment
Requested

 (c) Royalty Payments. 

(1) Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate.

 (2) LICENSEE shall pay earned royalties quarterly on or before February 28, May 31, August 31 and
November 30 of each calendar year. Each such payment shall be for earned royalties accrued within LICENSEE’s most recently completed calendar quarter. 
 (3) Royalties earned on sales occurring or under sublicense granted pursuant to this Agreement in any country outside the United States shall not be reduced by LICENSEE for any taxes, fees, or other
charges imposed by the government of such country on the payment of royalty income, except that all payments made by LICENSEE in fulfillment of UNIVERSITY’s tax liability in any particular country may be credited against earned royalties or
fees due UNIVERSITY for that country. LICENSEE shall pay all bank charges resulting from the transfer of such royalty payments. 
 (4) If at any time legal restrictions prevent the prompt remittance of part or all royalties by LICENSEE with respect to any country where a Licensed Product is sold or a sublicense is granted pursuant to
this Agreement, LICENSEE shall convert the amount owed to UNIVERSITY into US currency and shall pay UNIVERSITY directly from its US sources of fund for as long as the legal restrictions apply. 

(5) LICENSEE shall not collect royalties from, or cause to be paid on Licensed Products sold to the account of the US Government or any
agency thereof as provided for in the license to the US Government. 
 (6) In the event that any patent or patent claim within
Patent Rights is held invalid in a final decision by a patent office from which no appeal or additional patent prosecution has been or can be taken, or by a court of competent jurisdiction and last resort and from which no appeal has or can be
taken, all obligation to pay royalties based solely on that patent or claim or any claim patentably indistinct therefrom shall cease as of the date of such final decision. LICENSEE shall not, however, be relieved from paying any royalties that
accrued before the date of such final decision, that are based on another patent or claim not involved in such final decision, or that are based on the use of Technology. 
 (d) Late Payments. In the event royalty, reimbursement and/or fee payments are not received by UNIVERSITY when due, LICENSEE shall pay to UNIVERSITY interest charges at a rate of [...***...]
per year. Such interest shall be calculated from the date payment was due until actually received by UNIVERSITY. 

  

			
	13.	  	  
 ***Confidential Treatment
Requested

 ARTICLE 5 
 PATENT MATTERS 
 5.1 Patent Prosecution and Maintenance. 

(a) LICENSEE shall diligently prosecute and maintain the United States and, if available, foreign patents, and applications in
Patent Rights claiming the [...***...] Invention, at its own cost, using counsel of its choice. LICENSEE shall provide UNIVERSITY with copies of all relevant documentation relating to such prosecution and UNIVERSITY shall keep this
documentation confidential. 
 (b) Provided that LICENSEE has reimbursed UNIVERSITY for Patent Costs pursuant to
Paragraph 3.2, except as provided in Paragraph 5.1(a), UNIVERSITY shall diligently prosecute and maintain the United States and, if available, foreign patents, and applications in Patent Rights using counsel of its choice. UNIVERSITY shall
provide LICENSEE with copies of all relevant documentation relating to such prosecution and LICENSEE shall keep this documentation confidential. The counsel shall take instructions only from UNIVERSITY, and all patents and patent applications in
such Patent Rights shall be assigned solely to UNIVERSITY. 
 (c) UNIVERSITY shall consider amending any patent
application in Patent Rights to include claims reasonably requested by LICENSEE to protect the products contemplated to be sold by LICENSEE under this Agreement. 
 (d) LICENSEE shall apply for an extension of the term of any patent in Patent Rights if appropriate under the Drug Price Competition and Patent Term Restoration Act of 1984 and/or European,
Japanese and other foreign counterparts of this law. LICENSEE shall prepare all documents for such application, and UNIVERSITY shall execute such documents and to take any other additional action as LICENSEE reasonably requests in connection
therewith. 
 (e) LICENSEE may elect to terminate its obligations under Paragraph 5.1(a) or its reimbursement
obligations with respect to any patent application or patent in Patent Rights upon [...***...] written notice to UNIVERSITY. UNIVERSITY shall use reasonable efforts to curtail further Patent Costs for such application or patent when such
notice of termination is received from LICENSEE. UNIVERSITY, [...***...], may continue prosecution and maintenance of said application or patent, and LICENSEE shall then have no further license with respect thereto. Non-payment of any portion
of Patent Costs with respect to any application or patent may be deemed by UNIVERSITY as an election by LICENSEE to terminate its reimbursement obligations with respect to such application or patent. 

5.2 Patent Infringement. 
 (a) If LICENSEE learns of any substantial infringement of Patent Rights, LICENSEE shall so inform UNIVERSITY and provide UNIVERSITY with reasonable evidence of the infringement. Neither party shall
notify a third party of the infringement of Patent Rights 

  

			
	14.	  	  
 ***Confidential Treatment
Requested

 
without the consent of the other party. Both parties shall use reasonable efforts and cooperation to terminate infringement without litigation. 

(b) For [...***...] shall have the first right, but not the obligation, to enforce the Patents Rights
against any third party infringer. [...***...] agrees to provide [...***...] all reasonable assistance, at [...***...] expense, in such enforcement, including, without limitation, executing any necessary documentation related
thereto. If [...***...] fails to bring an action or proceeding [...***...], set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, then [...***...] shall have the right, but not the
obligation, to bring and control any such action at its own expense and by counsel of its own choice. In such case, [...***...] agrees to provide [...***...] all reasonable assistance, at [...***...] expense, in such enforcement,
including, without limitation, executing any necessary documentation related thereto. Regardless which party brings such enforcement action, the party not bringing the action shall have the right to participate in such action at its own expense with
its own counsel. 
 (c) Recoveries from actions brought pursuant to Paragraph 5.2(b) shall belong to
the party bringing suit, except that for suits brought by LICENSEE, a portion of any recovery, after reimbursement of all fees and costs incurred in connection with such suits, shall be paid to UNIVERSITY as follows: [...***...].
Legal actions brought jointly by UNIVERSITY and LICENSEE and fully participated in by both shall be [...***...]. 
 (d)
Each party shall cooperate with the other in litigation proceedings at the expense of the party bringing suit. Litigation shall be controlled by the party bringing the suit, except that UNIVERSITY may be represented by counsel of its choice in
any suit brought by LICENSEE. 
 5.3 Patent Marking. LICENSEE shall mark all Licensed Products made, used or sold under
the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws. 
 5.4
[...***...]. 

  

			
	15.	  	
		  	***Confidential Treatment Requested

 ARTICLE 6 
 GOVERNMENTAL MATTERS 
 6.1 Governmental Approval or Registration. If
this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency, LICENSEE shall assume all legal obligations to do so. LICENSEE shall notify UNIVERSITY if it becomes
aware that this Agreement is subject to a United States or foreign government reporting or approval requirement. LICENSEE shall make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with
such reporting or approval process. 
 6.2 Export Control Laws. LICENSEE shall observe all applicable United States and
foreign laws with respect to the transfer of Licensed Products and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations and the Export Administration Regulations. 

6.3 Preference for United States Industry. If LICENSEE sells a Licensed Product or Combination Product in the US, LICENSEE shall
manufacture said product substantially in the US. 
 ARTICLE 7 

TERMINATION OF THE AGREEMENT 
 7.1 Termination by The Regents. If LICENSEE fails to perform or violates any term of this Agreement, then UNIVERSITY may give written notice of default (“Notice of Default”) to LICENSEE.
If LICENSEE fails to cure the default within ninety (90) days of the Notice of Default, UNIVERSITY may terminate this Agreement and the license granted herein by a second written notice (“Notice of Termination”) to LICENSEE. If a
Notice of Termination is sent to LICENSEE, this Agreement shall automatically terminate on the effective date of that notice. Termination shall not relieve LICENSEE of its obligation to pay any fees owed at the time of termination and shall not
impair any accrued right of UNIVERSITY. 
 7.2 Termination by LICENSEE. 

(a) LICENSEE shall have the right at any time and for any reason to terminate this Agreement upon a ninety (90) day written
notice to UNIVERSITY. Said notice shall state LICENSEE’s reason for terminating this Agreement. 
 (b) Any
termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation or liability accrued under this Agreement prior to termination or rescind any payment made to UNIVERSITY or action by LICENSEE prior to the time termination becomes
effective. Termination shall not affect in any manner any rights of UNIVERSITY arising under this Agreement prior to termination. 

  

			
	16.	  	

 7.3 Survival on Termination. The following Paragraphs and Articles shall survive the
termination of this Agreement: 
  

	 	(a)	Paragraph 2.3(c); 

  

	 	(b)	Article 4 (REPORTS, RECORDS AND PAYMENTS); 

  

	 	(c)	Paragraph 5.4 [...***...]; 

  

	 	(d)	Paragraph 7.1 (Termination by the Regents); 

  

	 	(e)	Paragraph 7.2(b); 

  

	 	(f)	Paragraph 7.3 (Survival on Termination); 

  

	 	(g)	Paragraph 7.4 (Disposition of Licensed Products on Hand); 

  

	 	(h)	Paragraph 8.2 (Indemnification); 

  

	 	(i)	Article 9 (USE OF NAMES AND TRADEMARKS); 

  

	 	(j)	Paragraph 10.2 hereof (Secrecy); and 

  

	 	(k)	Paragraph 10.5 (Failure to Perform). 

 7.4 Disposition of Licensed Products on Hand. Upon termination of this Agreement, LICENSEE may dispose of all previously made or partially made Licensed Products within a period of
[...***...] provided that the sale of such Licensed Product by LICENSEE, its Sublicensees, or Affiliates shall be subject to the terms of this Agreement, including but not limited to the rendering of reports and payment of royalties required
under this Agreement. 
 ARTICLE 8 
 LIMITED WARRANTY AND INDEMNIFICATION 
 8.1 Limited Warranty.

 (a) UNIVERSITY warrants that it has the lawful right to grant the license it grants herein. 

(b) The license granted herein and the associated Technology are provided “AS IS” and without WARRANTY OF
MERCHANTABILITY or WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE or any other warranty, express or implied. UNIVERSITY makes no representation or warranty that the Licensed Product, Licensed Method or the use of Patent Rights or Technology will not
infringe any other patent or other proprietary rights. 

  

			
	17.	  	  
 ***Confidential Treatment
Requested

 (c) In no event shall UNIVERSITY be liable for any incidental, special or
consequential damages resulting from exercise of the license granted herein or the use of the Invention, Licensed Product, Licensed Method or Technology. 
 (d) Nothing in this Agreement shall be construed as: 
 (1) a warranty or
representation by UNIVERSITY as to the validity or scope of any Patent Rights; 
 (2) a warranty or representation that
anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or shall be free from infringement of patents of third parties; 
 (3) an obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in Paragraph 5.2 hereof; 

(4) conferring by implication, estoppel or otherwise any license or rights under any patents of UNIVERSITY other than Patent Rights as
defined in this Agreement, regardless of whether those patents are dominant or subordinate to Patent Rights; 
 (5) an
obligation to furnish any know-how not provided in Patent Rights and Technology; or 
 (6) an obligation to update Technology.

 8.2 Indemnification. 
 (a) LICENSEE shall indemnify, hold harmless and defend UNIVERSITY, its officers, employees, and agents; the sponsors of the research that led to the Invention; and the Inventors of the patents and
patent applications in Patent Rights and their employers against any and all claims, suits, losses, damage, costs, fees, and expenses incurred by any such party resulting from or arising out of [...***...]. This indemnification shall include,
but not be limited to, [...***...]. 
 (b) LICENSEE, at its sole cost and expense, shall insure its activities in
connection with the work under this Agreement and obtain, keep in force and maintain insurance or an equivalent program of self insurance as follows: 
 (1) comprehensive or commercial general liability insurance (contractual liability included) with limits of at least: (i) each occurrence, [...***...]; (ii) products/completed operations
aggregate, [...***...]; (iii) personal and advertising injury, [...***...]; and (iv) general aggregate (commercial form only), [...***...]; and 

(2) the coverage and limits referred to above shall not in any way limit the liability of LICENSEE. 

  

			
	18.	  	  
 ***Confidential Treatment
Requested

 (c) LICENSEE shall furnish UNIVERSITY with certificates of insurance showing
compliance with all requirements. Such certificates shall: (i) provide for thirty (30) day advance written notice to UNIVERSITY of any modification; (ii) indicate that UNIVERSITY has been endorsed as an additional insured under the
coverage referred to above; and (iii) include a provision that the coverage shall be primary and shall not participate with nor shall be excess over any valid and collectable insurance or program of self-insurance carried or maintained by
UNIVERSITY. 
 (d) UNIVERSITY shall notify LICENSEE in writing of any claim or suit brought against UNIVERSITY in respect
of which UNIVERSITY intends to invoke the provisions of this Article. LICENSEE shall keep UNIVERSITY informed on a current basis of its defense of any claims under this Article. 

ARTICLE 9 

USE OF NAMES AND TRADEMARKS 
 9.1 Nothing contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of either party
hereto (including contraction, abbreviation or simulation of any of the foregoing). Unless required by law, the use by LICENSEE of the name, “The Regents Of The University Of California” or the name of any campus of the University Of
California is prohibited, without the express written consent of UNIVERSITY. 
 9.2 UNIVERSITY may disclose to the
Inventors the terms and conditions of this Agreement upon their request. If such disclosure is made, UNIVERSITY shall request the Inventors not disclose such terms and conditions to others. 

9.3 UNIVERSITY may acknowledge the existence of this Agreement and the extent of the grant in Article 2 to third parties, but
UNIVERSITY shall not disclose the financial terms of this Agreement to third parties, except where UNIVERSITY is required by law to do so, such as under the California Public Records Act. 

9.4 LICENSEE shall be entitled to issue a press release announcing the execution of this Agreement and the general subject matter
hereof, provided that University must consent to the content of such press release, which consent shall not be unreasonably withheld or delayed. 
 ARTICLE 10 
 MISCELLANEOUS PROVISIONS 

10.1 Correspondence. Any notice or payment required to be given to either party under this Agreement shall be deemed to have been
properly given and effective: 
 (a) on the date of delivery if delivered in person, or 

  

			
	19.	  	

 (b) five (5) days after mailing if mailed by first-class or certified mail,
postage paid, to the respective addresses given below, or to such other address as is designated by written notice given to the other party. 
 If sent to LICENSEE: 
 Genomatica, Inc. 

5405, Morehouse Drive, Suite 210 
 San Diego, CA 92121 
 Attention: Chief Executive Officer 

Phone: (858) 824-1771 Fax: (858) 824-1772 
 If sent to UNIVERSITY: 
 University of California, San Diego 

Technology Transfer & Intellectual Property Services 
 9500 Gilman Drive 
 La Jolla, CA 92093-0910 

Attention: Director 
 Phone: (858) 534-5815 Fax: (858) 534-7345 
 10.2 Secrecy. 

(a) “Confidential Information” shall mean information, including Technology, relating to the Invention
and disclosed by UNIVERSITY to LICENSEE during the term of this Agreement, which if disclosed in writing shall be marked “Confidential”, or if first disclosed otherwise, shall within thirty (30) days of such disclosure be reduced to
writing by UNIVERSITY and sent to LICENSEE: 
 (c) LICENSEE shall: 

(1) use the Confidential Information for the sole purpose of performing under the terms of this Agreement; 

(2) safeguard Confidential Information against disclosure to others with the same degree of care as it exercises with its
own data of a similar nature; 
 (3) not disclose Confidential Information to others (except to its employees,
agents, consultants, Sublicensees, Third Party Partners, distributors or proposed Sublicensees, Third Party Partners or distributors, who are bound to LICENSEE by a like obligation of confidentiality) without the express written permission of
UNIVERSITY, except that LICENSEE shall not be prevented from using or disclosing any of the Confidential Information that: 
 (i) LICENSEE can demonstrate by written records was previously known to it; 

  

			
	20.	  	

 (ii) is now, or becomes in the future, public knowledge other than through
acts or omissions of LICENSEE; or 
 (iii) is lawfully obtained by LICENSEE from sources independent of
UNIVERSITY; and 
 (d) The secrecy obligations of LICENSEE with respect to Confidential Information
shall continue for a period ending [...***...] from the termination date of this Agreement. 
 10.2 Assignability.
This Agreement may be assigned by UNIVERSITY, but is personal to LICENSEE and assignable by LICENSEE only with the written consent of UNIVERSITY, which consent shall not be unreasonably withheld, except that Licensee can assign this Agreement to its
successor without prior written consent of UNIVERSITY provided that LICENSEE has sold all or substantially all of its business or assets that relate to this Agreement to such successor or in connection with the acquisition of LICENSEE by such
successor. 
 10.3 No Waiver. No waiver by either party of any breach or default of any covenant or agreement set forth
in this Agreement shall be deemed a waiver as to any subsequent and/or similar breach or default. 
 10.4 Failure to Perform.
In the event of a failure of performance due under this Agreement and if it becomes necessary for either party to undertake legal action against the other on account thereof, then the prevailing party shall be entitled to reasonable
attorney’s fees in addition to costs and necessary disbursements. 
 10.5 Governing Laws. THIS AGREEMENT SHALL BE
INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, but the scope and validity of any patent or patent application shall be governed by the applicable laws of the country of the patent or patent application. 

10.6 Force Majeure. A party to this Agreement may be excused from any performance required herein if such performance is rendered
impossible or unfeasible due to any catastrophe or other major event beyond its reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other
serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the non-performing party’s obligations herein shall resume. 

10.7 Headings. The headings of the several sections are inserted for convenience of reference only and are not intended to be a
part of or to affect the meaning or interpretation of this Agreement. 
 10.8 Entire Agreement. This Agreement embodies
the entire understanding of the parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof. The parties agree that the Prior Agreement is
terminated as of the Effective Date and is superseded in its entirety by this Agreement. 

  

			
	21.	  	  
 ***Confidential Treatment
Requested

 10.9 Amendments. No amendment or modification of this Agreement shall be valid or
binding on the parties unless made in writing and signed on behalf of each party. 
 10.10 Severability. In the event that
any of the provisions contained in this Agreement is held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be
construed as if the invalid, illegal, or unenforceable provisions had never been contained in it. 
 IN WITNESS WHEREOF, both
UNIVERSITY and LICENSEE have executed this Agreement, in duplicate originals, by their respective and duly authorized officers on the day and year written. 
  

									
	GENOMATICA, INC.	  		  	THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA:
					
	By:	 	 /s/ Thomas A. Reed
	  		  	By:	 	 /s/ Alan S. Paau

		 	    (Signature)	  		  		 	    (Signature)
					
	Name:	 	 Thomas A. Reed
	  		  	Name:	 	Alan S. Paau
					
	Title:	 	 Chief Financial Officer
	  		  	Title:	 	Director, Technology Transfer &
		 		  		  		 	Intellectual Property Services
					
	Date:	 	 December 20, 2001
	  		  	Date:	 	 December 20, 2001

  

			
	22.	  	

 EXHIBIT A 

STOCK PURCHASE AGREEMENT 

AND 
 RESTATED ARTICLES OF INCORPORATION 

 GENOMATICA, INC. 

SERIES A-1 PREFERRED STOCKHOLDER AGREEMENT 

[...***...] 

***Confidential Treatment Requested 

 SECOND AMENDED AND RESTATED ARTICLES OF INCORPORATION 

OF 

GENOMATICA, INC. 
 Bernhard O. Palsson hereby certifies that: 
 ONE: He is the duly elected
and acting President and Secretary of Genomatica, Inc., a California corporation (the “Corporation”). 
 TWO:
The Articles of Incorporation of this Corporation, originally filed November 23, 1998, amended on May 4, 2000, amended and restated on March 15, 2001, and amended and restated on April 24, 2001 are hereby amended and restated
to read as follows: 
 I. 
 The name of the Corporation is GENOMATICA, INC. 
 II. 
 The purpose of the Corporation is to engage in any lawful act or
activity for which a corporation may be organized under the General Corporation Law of California other than the banking business, the trust company business or the practice of a profession permitted to be incorporated by the California Corporations
Code. 
 III. 
 A. This Corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the
Corporation is authorized to issue is thirty million (30,000,000) shares, twenty million (20,000,000) shares of which shall be Common Stock (the “Common Stock”) and ten million (10,000,000) shares of which shall be Preferred
Stock (the “Preferred Stock”). 
 B. The Preferred Stock may be issued from time to time in one or more series.
The Board of Directors is hereby authorized, within the limitations and restrictions stated in these Second Amended and Restated Articles of Incorporation, to fix or alter the dividend rights, dividend rate, conversion rights, voting rights, rights
and terms of redemption (including sinking fund provisions), the redemption price or prices, the liquidation preferences of any wholly unissued series of Preferred Stock, and the number of shares constituting any such series and the designation
thereof, or any of them; and to increase or decrease the number of shares of any series subsequent to the issue of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series
shall be so decreased, the shares constituting such decrease shall resume the status which they had prior to the adoption of the resolution originally fixing the number of shares of such series. 

C. Three million (3,000,000) of the authorized shares of Preferred Stock are hereby designated “Series A Preferred
Stock” (the “Series A Preferred Stock”). Three hundred fifty 

  
 1. 

 
thousand (350,000) of the authorized shares of Preferred Stock are hereby designated “Series A-1 Preferred Stock” (the “Series A-1 Preferred Stock” and, collectively with
the Series A Preferred Stock, the “Series Preferred”). 
 D. The rights, preferences, privileges, restrictions
and other matters relating to the Series Preferred are as follows: 
 1. DIVIDEND RIGHTS.

 a. Holders of Series Preferred, in preference to the holders of any other stock of the Corporation (“Junior
Stock”), shall be entitled to receive, if, when and as declared by the Board of Directors, but only out of funds that are legally available therefor, cash dividends at the rate of eight percent (8%) of the applicable “Original Issue
Price” per annum on each outstanding share of Series Preferred (as adjusted for any stock dividends, combinations, splits recapitalizations and the like with respect to such shares). The Original Issue Price of the Series A Preferred Stock
shall be one dollar ($1.00) per share (the “Series A Original Issue Price”). The Original Issue Price of the Series A-1 Preferred Stock shall be one dollar ($1.00) per share (the “Series A-1 Original Issue Price”). Such
dividends shall be payable only when, as and if declared by the Board of Directors and shall be non-cumulative. 
 b. So
long as any shares of Series Preferred shall be outstanding, no dividend, whether in cash or property, shall be paid or declared, nor shall any other distribution be made, on any Junior Stock, nor shall any shares of any Junior Stock of the
Corporation be purchased, redeemed, or otherwise acquired for value by the Corporation (except for acquisitions of Common Stock by the Corporation pursuant to agreements which permit the Corporation to repurchase such shares upon termination of
services to the Corporation or in exercise of the Corporation’s right of first refusal upon a proposed transfer) until all dividends (set forth in Section 1(a) above) on the Series Preferred shall have been paid or declared and set apart.
The provisions of this Section 1(b) shall not, however, apply to (i) a dividend payable in Common Stock, (ii) the acquisition of shares of any Junior Stock in exchange for shares of any other Junior Stock, or (iii) any repurchase
of any outstanding securities of the Corporation that is unanimously approved by the Corporation’s Board of Directors. The holders of the Series Preferred expressly waive their rights, if any, as described in California Corporations Code
Sections 502, 503 and 506 as they relate to repurchase of shares upon termination of employment. 
 2. VOTING
RIGHTS. Except as otherwise provided herein or as required by law, the Series Preferred shall be voted equally with the shares of the Common Stock of the Corporation and not as a separate class, at any annual or special meeting of
shareholders of the Corporation, and may act by written consent in the same manner as the Common Stock, in either case upon the following basis: each holder of shares of Series Preferred shall be entitled to such number of votes as shall be equal to
the whole number of shares of Common Stock into which such holder’s aggregate number of shares of Series Preferred are convertible (pursuant to Section 4 hereof) immediately after the close of business on the record date fixed for such
meeting or the effective date of such written consent. 

  
 2. 

 3. LIQUIDATION RIGHTS. 

a. Upon any liquidation, dissolution, or winding up of the Corporation, whether voluntary or involuntary, before any distribution
or payment shall be made to the holders of Series A-1 Preferred Stock or holders of any Junior Stock, the holders of Series A Preferred Stock shall be entitled to be paid out of the assets of the Corporation an amount per share of Series A Preferred
Stock equal to the Series A Original Issue Price plus all declared and unpaid dividends on such shares (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares) for each share of
Series A Preferred Stock held by them. If, upon any liquidation, distribution, or winding up, the assets of the Corporation shall be insufficient to make payment in full to all holders of Series A Preferred Stock of the liquidation preference set
forth above, then such assets shall be distributed among the holders of Series A Preferred Stock at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled. 

b. After the payment of the full liquidation preference of the Series A Preferred Stock as set forth in Section 3(a) above,
and before any distribution or payment shall be made to the holders of any Junior Stock, the holders of Series A-1 Preferred Stock shall be entitled to be paid out of the assets of the Corporation an amount per share of Series A-1 Preferred Stock
equal to the Series A-1 Original Issue Price plus all declared and unpaid dividends on such shares (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares) for each share of Series
A-1 Preferred Stock held by them. If, upon any liquidation, distribution, or winding up, after payment of the full liquidation preference of the Series A Preferred Stock as set forth in Section 3(a) above the assets of the Corporation shall be
insufficient to make payment in full to all holders of Series A-1 Preferred Stock of the liquidation preference set forth above, then such assets shall be distributed among the holders of Series A-1 Preferred Stock at the time outstanding, ratably
in proportion to the full amounts to which they would otherwise be respectively entitled. 
 c. After the payment of the
full liquidation preference of the Series A Preferred Stock as set forth in Section 3(a) above and payment of the full liquidation preference of the Series A-1 Preferred Stock as set forth in Section 3(b) above, the assets of the
Corporation legally available for distribution, if any, shall be distributed ratably to the holders of the Common Stock and Series A Preferred Stock on an as-if-converted to Common Stock basis until such time as the holders of Series A Preferred
Stock have received pursuant to Section 3(a) above and this Section 3(b) an aggregate amount per share of Series A Preferred Stock equal to two (2) times the Series A Original Issue Price (as adjusted for any stock dividends,
combinations, splits, recapitalizations and the like with respect to the Series Preferred). The remaining assets of the Corporation legally available for distribution, if any, shall be distributed ratably to the holders of Common Stock. 

d. A consolidation or merger of the Corporation with or into any other corporation or other entity or person, or any other
corporate reorganization, or a sale, lease or other disposition of all or substantially all of the assets of the Corporation shall not be deemed to be a liquidation, dissolution or winding up within the meaning of this Section 3. 

  
 3. 

 e. If any of the assets of the Corporation are to be distributed other than in cash
under this Section 3 or for any purpose, then the Board of Directors of the Corporation shall promptly engage independent competent appraisers to determine the value of the assets to be distributed to the holders of Series Preferred or Common
Stock. The Corporation shall, upon receipt of such appraiser’s valuation, give prompt written notice to each holder of shares of Series Preferred or Common Stock of the appraiser’s valuation. 

4. CONVERSION RIGHTS. 
 The holders of the Series Preferred shall have the following rights with respect to the conversion of the Series Preferred into shares of Common Stock (the “Conversion Rights”): 

a. Optional Conversion. Subject to and in compliance with the provisions of this Section 4, each share of Series Preferred
may, at the option of the holder, be converted at any time into such number of fully-paid and nonassessable shares of Common Stock as is determined (i) as to the Series A Preferred Stock, by dividing $1.00 by the then effective Conversion Price
for the Series A Preferred Stock, and (ii) as to the Series A-1 Preferred Stock, by dividing $1.00 by the then effective Conversion Price for the Series A-1 Preferred Stock (in each case as last adjusted and then currently in effect, referred
to as the “Conversion Price”). The Conversion Price per share at which shares of Common Stock shall initially be issuable (the “Initial Conversion Price”) upon conversion of the Series Preferred shall be $1.00 with respect to the
Series A Preferred Stock and $1.00 with respect to the Series A-1 Preferred Stock; provided, however, that such Conversion Price shall be subject to adjustment at any time and from time to time after the date upon which the first share of Series A-1
Preferred Stock is issued (the “Original Issue Date”). 
 b. Mechanics of Conversion. Each holder of Series
Preferred who desires to convert the same into shares of Common Stock pursuant to this Section 4 shall surrender the certificate or certificates therefor, duly endorsed, at the office of the Corporation or any transfer agent for the Series
Preferred, and shall give written notice to the Corporation at such office that such holder elects to convert the same. Such notice shall state the number of shares of Series Preferred being converted. Thereupon, the Corporation shall promptly issue
and deliver at such office to such holder a certificate or certificates for the number of shares of Common Stock to which such holder is entitled and shall promptly pay in cash or, to the extent sufficient funds are not then legally available
therefor, in Common Stock (at the Common Stock’s fair market value determined by the Board of Directors as of the date of such conversion), any declared and unpaid dividends on the shares of Series Preferred being converted. Such conversion
shall be deemed to have been made at the close of business on the date of such surrender of the certificates representing the shares of Series Preferred to be converted, and the person entitled to receive the shares of Common Stock issuable upon
such conversion shall be treated for all purposes as the record holder of such shares of Common Stock on such date. 
 c.
Adjustment for Stock Splits and Combinations. If the Corporation shall at any time or from time to time after the Original Issue Date effect a subdivision of the outstanding Common Stock without a corresponding subdivision of the Preferred
Stock, the Conversion Price with respect to each series of Preferred Stock in effect 

  
 4. 

 
immediately before that subdivision shall be proportionately decreased. Conversely, if the Corporation shall at any time or from time to time after the Original Issue Date combine the outstanding
shares of Common Stock into a smaller number of shares without a corresponding combination of the Preferred Stock, the Conversion Price with respect to each series of Preferred Stock in effect immediately before the combination shall be
proportionately increased. Any adjustment under this Section 4(c) shall become effective at the close of business on the date the subdivision or combination becomes effective. 

d. Adjustment for Common Stock Dividends and Distributions. If the Corporation at any time or from time to time after the
Original Issue Date makes, or fixes a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in additional shares of Common Stock, in each such event the Conversion Price with
respect to each series of Preferred Stock that is then in effect shall be decreased as of the time of such issuance or, in the event such record date is fixed, as of the close of business on such record date, by multiplying the Conversion Price with
respect to each series of Preferred Stock then in effect by a fraction (i) the numerator of which is the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on
such record date, and (ii) the denominator of which is the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of
Common Stock issuable in payment of such dividend or distribution; provided, however, that if such record date is fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the Conversion Price
with respect to each series of Preferred Stock shall be recomputed accordingly as of the close of business on such record date and thereafter the Conversion Price with respect to each series of Preferred Stock shall be adjusted pursuant to this
Section 4(d) to reflect the actual payment of such dividend or distribution. 
 e. Adjustment for Reclassification,
Exchange and Substitution. If at any time or from time to time after the Original Issue Date, the Common Stock issuable upon the conversion of the Series Preferred is changed into the same or a different number of shares of any class or classes
of stock, whether by recapitalization, reclassification or otherwise (other than as a result of a subdivision or combination of shares or stock dividend or a reorganization, merger or consolidation in which the Corporation is the continuing entity
and which does not result in any change in the Common Stock) in any such event the Series Preferred shall be convertible into the kind and amount of stock and other securities and property receivable upon such recapitalization, reclassification or
other change by holders of the maximum number of shares of Common Stock into which such shares of Series Preferred could have been converted immediately prior to such recapitalization, reclassification or change, all subject to further adjustment as
provided herein or with respect to such other securities or property by the terms thereof. 
 f. Reorganizations, Mergers,
Consolidations or Sales of Assets. If at any time or from time to time after the Original Issue Date, there is a capital reorganization of the Common Stock (other than a recapitalization, subdivision, combination, reclassification, exchange or
substitution of shares), as a part of such capital reorganization, provision shall be made so that the holders of the Series Preferred shall thereafter be entitled to receive upon conversion of the Series Preferred the number of shares of stock or
other securities or property of 

  
 5. 

 
the Corporation to which a holder of the number of shares of Common Stock deliverable upon conversion would have been entitled on such capital reorganization, subject to adjustment in respect of
such stock or securities by the terms thereof. In any such case, appropriate adjustment shall be made in the application of the provisions of this Section 4 with respect to the rights of the holders of Series Preferred after the capital
reorganization to the end that the provisions of this Section 4 (including adjustment of the Conversion Price with respect to each series of Preferred Stock then in effect and the number of shares issuable upon conversion of the Series
Preferred) shall be applicable after that event and be as nearly equivalent as practicable. 
 g. Sale of Shares Below
Series Preferred Conversion Price. 
 (i) If at any time or from time to time after the Original Issue Date, the
Corporation issues or sells, or is deemed by the express provisions of this subsection (g) to have issued or sold, Additional Shares of Common Stock (as defined in subsection (g)(iv) below)), other than as a dividend or other distribution on
any class of stock as provided in Section 4(d) above, and other than a subdivision or combination of shares of Common Stock as provided in Section 4(c) above, for an Effective Price (as defined in subsection (g)(iv) below) less than the
Conversion Price with respect to any series of Preferred Stock then in effect, then and in each such case, such Conversion Price shall be reduced, as of the opening of business on the date of such issue or sale, to a price determined by multiplying
such Conversion Price by a fraction (x) the numerator of which shall be (A) the number of shares of Common Stock deemed outstanding (as defined below) immediately prior to such issue or sale, plus (B) the number of shares of Common
Stock which the aggregate consideration received (as defined in subsection (g)(ii)) by the Corporation for the total number of Additional Shares of Common Stock so issued would purchase at such Conversion Price, and (y) the denominator of which
shall be the number of shares of Common Stock deemed outstanding (as defined below) immediately prior to such issue or sale plus the total number of Additional Shares of Common Stock so issued. For the purposes of the preceding sentence, the number
of shares of Common Stock deemed to be outstanding as of a given date shall be the sum of (A) the number of shares of Common Stock actually outstanding, (B) the number of shares of Common Stock into which the then outstanding shares of
Series Preferred could be converted if fully converted on the day immediately preceding the given date, and (C) the number of shares of Common Stock which could be obtained through the exercise or conversion of all other rights, options and
convertible securities outstanding or exercisable on the day immediately preceding the given date. 
 (ii) For the
purpose of making any adjustment required under this Section 4(g), the consideration received by the Corporation for any issue or sale of securities shall (A) to the extent it consists of cash, be computed at the net amount of cash
received by the Corporation after deduction of any underwriting or similar commissions, compensation or concessions paid or allowed by the Corporation in connection with such issue or sale but without deduction of any expenses payable by the
Corporation, (B) to the extent it consists of property other than cash, be computed at the fair value of that property as determined in good faith by the Board of Directors, and (C) if Additional Shares of Common Stock, Convertible
Securities (as defined in subsection (g)(iii) below) or rights or options to purchase either Additional Shares of Common Stock or Convertible Securities are issued or sold together with other stock or securities or other assets of the Corporation
for a consideration which covers both, be computed 

  
 6. 

 
as the portion of the consideration so received that may be reasonably determined in good faith by the Board of Directors to be allocable to such Additional Shares of Common Stock, Convertible
Securities or rights or options. 
 (iii) For the purpose of the adjustment required under this Section 4(g), if
the Corporation issues or sells any (i) stock or other securities convertible into, Additional Shares of Common Stock (such convertible stock or securities being herein referred to as “Convertible Securities”) or (ii) rights or
options for the purchase of Additional Shares of Common Stock or Convertible Securities and if the Effective Price of such Additional Shares of Common Stock is less than the Conversion Price with respect to any series of Preferred Stock then in
effect, in each case the Corporation shall be deemed to have issued at the time of the issuance of such rights or options or Convertible Securities the maximum number of Additional Shares of Common Stock issuable upon exercise or conversion thereof
and to have received as consideration for the issuance of such shares an amount equal to the total amount of the consideration, if any, received by the Corporation for the issuance of such rights or options or Convertible Securities, plus, in the
case of such rights or options, the minimum amounts of consideration, if any, payable to the Corporation upon the exercise of such rights or options, plus, in the case of Convertible Securities, the minimum amounts of consideration, if any, payable
to the Corporation (other than by cancellation of liabilities or obligations evidenced by such Convertible Securities) upon the conversion thereof; provided that if in the case of Convertible Securities the minimum amounts of such consideration
cannot be ascertained, but are a function of antidilution or similar protective clauses, the Corporation shall be deemed to have received the minimum amounts of consideration without reference to such clauses; provided further that if the minimum
amount of consideration payable to the Corporation upon the exercise or conversion of rights, options or Convertible Securities is reduced over time or on the occurrence or non-occurrence of specified events other than by reason of antidilution
adjustments, the Effective Price shall be recalculated using the figure to which such minimum amount of consideration is reduced; provided further that if the minimum amount of consideration payable to the Corporation upon the exercise or conversion
of such rights, options or Convertible Securities is subsequently increased, the Effective Price shall be again recalculated using the increased minimum amount of consideration payable to the Corporation upon the exercise or conversion of such
rights, options or Convertible Securities. No further adjustment of such Conversion Price, as adjusted upon the issuance of such rights, options or Convertible Securities, shall be made as a result of the actual issuance of Additional Shares of
Common Stock on the exercise of any such rights or options or the conversion of any such Convertible Securities. If any such rights or options or the conversion privilege represented by any such Convertible Securities shall expire without having
been exercised, such Conversion Price as adjusted upon the issuance of such rights, options or Convertible Securities shall be readjusted to the Conversion Price which would have been in effect had an adjustment been made on the basis that the only
Additional Shares of Common Stock so issued were the Additional Shares of Common Stock, if any, actually issued or sold on the exercise of such rights or options or rights of conversion of such Convertible Securities, and such Additional Shares of
Common Stock, if any, were issued or sold for the consideration actually received by the Corporation upon such exercise, plus the consideration, if any, actually received by the Corporation for the granting of all such rights or options, whether or
not exercised, plus the consideration received for issuing or selling the Convertible Securities actually converted, plus the consideration, if any, actually received by the Corporation (other than by cancellation of

  
 7. 

 
liabilities or obligations evidenced by such Convertible Securities) on the conversion of such Convertible Securities; provided that such readjustment shall not apply to prior conversions of
Series Preferred. 
 (iv) “Additional Shares of Common Stock” shall mean all shares of Common Stock issued by
the Corporation or deemed to be issued pursuant to this Section 4(g), whether or not subsequently reacquired or retired by the Corporation other than (A) shares of Common Stock issued upon conversion of the Series Preferred;
(B) shares of Common Stock and/or options, warrants or other Common Stock purchase rights and the Common Stock issued pursuant to such options, warrant or other rights (as adjusted for any stock dividends, combinations, splits,
recapitalizations and the like) issued or granted after the Original Issue Date to employees, officers or directors of, or consultants or advisors to the Corporation or any subsidiary pursuant to stock purchase or stock option plans or other
arrangements that are approved by the Board; (C) shares of Common Stock issued pursuant to the exercise of options, warrants or convertible securities outstanding as of the Original Issue Date; (D) shares of Common Stock issued for
consideration other than cash pursuant to a merger, consolidation, acquisition or similar business combination; (E) shares of Common Stock issued pursuant to any equipment leasing arrangement, or debt financing from a bank or similar financial
institution; (F) shares of Common Stock, Preferred Stock, options, warrants or other equity securities issued in connection with strategic transactions involving the Corporation and other entities, including (x) joint venture,
manufacturing, marketing or distribution arrangements and (y) technology transfer, collaboration, licensing or development arrangements; provided that such strategic transactions and the related issuance of equity securities have been approved
by the Board; and (G) options issued pursuant to any plan or other arrangement approved by the Board (as well as any shares issued upon exercise thereof). The “Effective Price” of Additional Shares of Common Stock shall mean the
quotient determined by dividing the total number of Additional Shares of Common Stock issued or sold, or deemed to have been issued or sold by the Corporation under this Section 4(g), into the aggregate consideration received, or deemed to have
been received by the Corporation for such issue under this Section 4(g), for such Additional Shares of Common Stock. 

h. Certificate of Adjustment. 
 (i) In each case of an adjustment or readjustment of the Conversion Price with respect to the Series A Preferred Stock for the number of shares of Common Stock or other securities issuable
upon conversion of the Series A Preferred Stock, if the Series A Preferred Stock is then convertible pursuant to this Section 4, the Corporation, at its expense, shall compute such adjustment or readjustment in accordance with the provisions
hereof and prepare a certificate showing such adjustment or readjustment, and shall mail such certificate, by first class mail, postage prepaid, to each registered holder of Series A Preferred Stock at the holder’s address as shown in the
Corporation’s books. The certificate shall set forth such adjustment or readjustment, showing in detail the facts upon which such adjustment or readjustment is based, including a statement of (i) the consideration received or deemed to be
received by the Corporation for any Additional Shares of Common Stock issued or sold or deemed to have been issued or sold, (ii) the Conversion Price with respect to the Series A Preferred Stock then in effect, (iii) the number of
Additional Shares of Common Stock and (iv)

  
 8. 

 
the type and amount, if any, of other property which at the time would be received upon conversion of the Series A Preferred Stock. 

(ii) In each case of an adjustment or readjustment of the Conversion Price with respect to the Series A-1 Preferred Stock
for the number of shares of Common Stock or other securities issuable upon conversion of the Series A-1 Preferred Stock, if the Series A-1 Preferred Stock is then convertible pursuant to this Section 4, the Corporation, at its expense, shall
compute such adjustment or readjustment in accordance with the provisions hereof and prepare a certificate showing such adjustment or readjustment, and shall mail such certificate, by first class mail, postage prepaid, to each registered holder of
Series A-1 Preferred Stock at the holder’s address as shown in the Corporation’s books. The certificate shall set forth such adjustment or readjustment, showing in detail the facts upon which such adjustment or readjustment is based,
including a statement of (i) the consideration received or deemed to be received by the Corporation for any Additional Shares of Common Stock issued or sold or deemed to have been issued or sold, (ii) the Conversion Price with respect to
the Series A-1 Preferred Stock then in effect, (iii) the number of Additional Shares of Common Stock and (iv) the type and amount, if any, of other property which at the time would be received upon conversion of the Series A-1
Preferred Stock. 
 i. Notices of Record Date. Upon (i) any taking by the Corporation of a record of the holders of
any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, or (ii) any capital reorganization of the Corporation, any reclassification or recapitalization of the
capital stock of the Corporation, any merger or consolidation of the Corporation with or into any other corporation, or any voluntary or involuntary dissolution, liquidation or winding up of the Corporation, the Corporation shall mail to each holder
of Series Preferred at least twenty (20) days prior to the record date specified therein a notice specifying (A) the date on which any such record is to be taken for the purpose of such dividend or distribution and a description of such
dividend or distribution, (B) the date on which any such reorganization, reclassification, transfer, consolidation, merger, dissolution, liquidation or winding up is expected to become effective, and (C) the date, if any, that is to be
fixed as to when the holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common Stock (or other securities) for securities or other property deliverable upon such reorganization, reclassification,
transfer, consolidation, merger, dissolution, liquidation or winding up. 
 j. Automatic Conversion. 

(i) Each share of Series Preferred shall automatically be converted into shares of Common Stock, based on the applicable
Conversion Price with respect to each series of Preferred Stock then in effect, (A) at any time upon the affirmative election of the holders of at least a majority of the outstanding shares of the Series Preferred, or (B) immediately upon
the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of Common Stock for the account of the Corporation in which (i) the
per share price is at least $3.00 (as adjusted for stock splits, dividends, recapitalizations and the like), and (ii) the gross cash proceeds to the Corporation (before underwriting discounts, commissions and fees) are at

  
 9. 

 
least $10,000,000. Upon such automatic conversion, any declared and unpaid dividends shall be paid in accordance with the provisions of Section 4(b). 

(ii) Upon the occurrence of either event specified in paragraph (i) above, the outstanding shares of Series Preferred shall
be converted automatically without any further action by the holders of such shares and whether or not the certificates representing such shares are surrendered to the Corporation or its transfer agent; provided, however, that the Corporation shall
not be obligated to issue certificates evidencing the shares of Common Stock issuable upon such conversion unless the certificates evidencing such shares of Series Preferred are either delivered to the Corporation or its transfer agent as provided
below, or the holder notifies the Corporation or its transfer agent that such certificates have been lost, stolen or destroyed and executes an agreement satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in
connection with such certificates. Upon the occurrence of such automatic conversion of the Series Preferred, the holders of Series Preferred shall surrender the certificates representing such shares at the office of the Corporation or any transfer
agent for the Series Preferred. Thereupon, there shall be issued and delivered to such holder promptly at such office and in its name as shown on such surrendered certificate or certificates, a certificate or certificates for the number of shares of
Common Stock into which the shares of Series Preferred surrendered were convertible on the date on which such automatic conversion occurred, and any declared and unpaid dividends shall be paid in accordance with the provisions of Section 4(b).

 k. Fractional Shares. No fractional shares of Common Stock shall be issued upon conversion of Series Preferred. All
shares of Common Stock (including fractions thereof) issuable upon conversion of more than one share of Series Preferred by a holder thereof shall be aggregated for purposes of determining whether the conversion would result in the issuance of any
fractional share. If, after the aforementioned aggregation, the conversion would result in the issuance of any fractional share, the Corporation shall, in lieu of issuing any fractional share, pay cash equal to the product of such fraction
multiplied by the Common Stock’s fair market value (as determined by the Board of Directors) on the date of conversion. 

l. Reservation of Stock Issuable Upon Conversion. The Corporation shall at all times reserve and keep available out of its
authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of the shares of the Series Preferred, such number of its shares of Common Stock as shall from time to time be sufficient to effect the conversion of
all outstanding shares of the Series Preferred. If at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Series Preferred, the Corporation will
take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose. 

m. Notices. Any notice required by the provisions of this Section 4 shall be in writing and shall be deemed effectively
given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after
having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) day after 

  
 10.

 
deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices shall be addressed to each holder of record at the address
of such holder appearing on the books of the Corporation. 
 n. Payment of Taxes. The Corporation will pay all taxes
(other than taxes based upon income) and other governmental charges that may be imposed with respect to the issue or delivery of shares of Common Stock upon conversion of shares of Series Preferred, excluding any tax or other charge imposed in
connection with any transfer involved in the issue and delivery of shares of Common Stock in a name other than that in which the shares of Series Preferred so converted were registered. 

o. No Dilution or Impairment. Without the consent of the holders of the then outstanding Series Preferred, voting together as a
single class, the Corporation shall not amend its Second Amended and Restated Articles of Incorporation or participate in any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or take any other
voluntary action, for the purpose of avoiding or seeking to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Corporation, but shall at all times in good faith assist in carrying out all such action
as may be reasonably necessary or appropriate in order to protect the conversion rights of the holders of the Series Preferred against dilution or other impairment. 
 5. NO REISSUANCE OF SERIES PREFERRED. 
 No share or shares of Series Preferred which have been converted into Common Stock after the original issuance thereof shall be reissued and all such shares so converted shall upon such conversion cease
to be authorized shares of the Corporation. In addition, the Articles of Incorporation shall be appropriately amended to effect the corresponding reduction in the Corporation’s authorized stock. 

6. NO PREEMPTIVE RIGHTS. 

Shareholders shall have no preemptive rights. 
 IV. 
 A. The liability of the directors of the Corporation for
monetary damages shall be eliminated to the fullest extent permissible under California law. 
 B. The Corporation is
authorized to provide indemnification of agents (as defined in Section 317 of the General Corporation Law of California) for breach of duty to the Corporation and its shareholders through bylaw provisions or through agreements with agents, or
both, in excess of the indemnification otherwise permitted by Section 317 of the General Corporation Law of California, subject to the limits on such excess indemnification set forth in Section 204 of the General Corporation Law of
California. If, after the effective date of this Article, California law is amended in a manner which permits a corporation to limit the monetary or other liability of its directors or to authorize indemnification of, or advancement of such defense
expenses to, its directors or other persons, in any such case to a greater extent than is permitted on such 

  
 11.

 
effective date, the references in this Article to “California law” shall to that extent be deemed to refer to California law as so amended. 

C. Any repeal or modification of this Article shall only be prospective and shall not effect the rights under this Article in
effect at the time of the alleged occurrence of any action or omission to act giving rise to liability. 
 THREE: The
foregoing amendment and restatement of the Articles of Incorporation has been duly approved by the Board of Directors of this Corporation. 
 FOUR: The foregoing amendment and restatement of the Articles of Incorporation has been duly approved by the required vote of shareholders in accordance with Section 902 of the California
Corporations Code. The Corporation has two classes of stock outstanding and each such class of stock is entitled to vote with respect to the amendment herein set forth. The total number of outstanding shares of the Corporation is 3,360,000 shares of
Common Stock and 3,000,000 shares of Series A Preferred Stock. The number of shares voting in favor of the amendment equaled or exceeded the vote required. The percentage vote required was more than fifty percent (50%) of the outstanding Common
Stock voting as a class and more than fifty percent (50%) of the outstanding Series A Preferred Stock voting as a class. There are no shares of Series A-1 Preferred Stock outstanding. 

[THIS SPACE INTENTIONALLY LEFT BLANK] 

  
 12.

 The undersigned, Bernhard O. Palsson, the President and Secretary of
GENOMATICA, INC., declares under penalty of perjury under the laws of the State of California that the matters set out in the foregoing Certificate are true of his own knowledge. 

Executed at San Diego, California on December 18, 2001. 

 

	
	 /s/ Bernhard O. Palsson

	Bernhard O. Palsson
	President and Secretary

  
 13.

 EXHIBIT B 
 ASSIGNMENT OF [...***...] INVENTION 
 [...***...] 

***Confidential Treatment Requested 

 AMENDMENT NO. 1 TO THE LICENSE AGREEMENT 

EFFECTIVE 20 DECEMBER 2001 
 BETWEEN 
 GENOMATICA, INC., 

AND 
 THE
REGENTS OF THE UNIVERSITY OF CALIFORNIA 
 FOR 
 UCSD DOCKET NOs. [...***...] 
 This amendment to the
agreement (“Amendment”) is made by and between Genomatica, Inc, a California corporation having an address at 5405 Morehouse Drive, Suite 210, San Diego, CA 92121 (“Genomatica”) and The Regents Of The University Of California, a
California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“University”), as represented by its San Diego campus having an address at University of California, San
Diego, Technology Transfer & Intellectual Property Services, Mail-code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UCSD”). 
 This Amendment is effective on the date of the last signature (“Effective Date”). 
 Whereas, Genomatica has entered into a License Agreement (“License Agreement”) with the UNIVERSITY effective 20 December 2001 (UC control No. 2002-04-0215) wherein Genomatica
was granted certain rights; 
 Whereas, Genomatica and University wish to amend the License Agreement; 

Now Therefore, Genomatica and University agree to amend the License Agreement to include certain modifications. These changes are
to be substituted for those relevant portions in the License Agreement and are effective on the Effective Date. For these purposes, changes are made as detailed below to the following Articles of the License Agreement: 

ARTICLE 2. GRANTS. 
 2.2(c) is replaced
in its entirety with the following: 
 Upon termination of this Agreement for any reason, UNIVERSITY, at its reasonable discretion, shall
determine whether LICENSEE shall cancel or assign to UNIVERSITY any and all sublicenses; provided, however, that LICENSEE may submit a proposed sublicense to UNIVERSITY in advance for UNIVERSITY’s prior approval, such approval not to be
unreasonably withheld or delayed (i.e. UNIVERSITY will respond within forty-five (45) days after receipt of such proposal from LICENSEE), and if UNIVERSITY approves such sublicense, then such sublicense shall also become a direct license
between the Sublicensee and UNIVERSITY upon termination of this Agreement for any reason, provided that such Sublicensee is not the cause of the termination of this 

  

			
		  	  
 ***Confidential Treatment
Requested

 Agreement, but the UNIVERSITY’S duties under any assumed sublicense shall be only to the extent of the
UNIVERSITY’S duties under this license. 
 ARTICLE 5. PATENT MATTERS 
 5.2 (a) is replaced in its entirety with the following: 
 If LICENSEE learns of any
substantial infringement of Patent Rights, LICENSEE shall so inform UNIVERSITY promptly and provide UNIVERSITY with reasonable evidence of the infringement. Neither party shall notify a third party of the infringement of Patent Rights without the
consent of the other party. Both parties shall use reasonable efforts and cooperation to terminate infringement without litigation. 
 5.2
(b) is replaced in its entirety with the following: 
 [...***...] agrees to provide [...***...] all
reasonable assistance [...***...], in such enforcement, including, without limitation, executing any necessary documentation related thereto. If [...***...] fails to bring an action or proceeding within [...***...] set forth in the
appropriate laws and regulations for the filing of such actions, whichever comes first, then [...***...] shall have the right, but not the obligation, to bring and control any such action at its own expense and by counsel of its own choice. In
such case, [...***...] agrees to provide [...***...] all reasonable assistance, at [...***...] expense, in such enforcement, including, without limitation, executing any necessary documentation related thereto. Regardless which
party brings such enforcement action, the party not bringing the action shall have the right to participate in such action at its own expense with its own counsel. [...***...] may not make the [...***...] a party to an infringement
action brought by [...***...] without [...***...] consent. 
 All other terms and conditions in the Agreement between Genomatica and
The University effective 20 December 2001 shall remain unchanged and in effect. The parties agree that this Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original and all of which together
shall constitute but one and the same instrument. 
 IN WITNESS WHEREOF, both UNIVERSITY and Genomatica have executed this Agreement, in
duplicate originals, by their respective and duly authorized officers on the day and year written. 
  

									
	GENOMATICA, INC.:	 		 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA:
					
	By:	 	 /s/ Thomas A. Reed
	 		 	By:	 	 /s/ Alan S. Paau

		 	     Thomas A. Reed	 		 		 	     Alan S. Paau
		 	     Chief Financial Officer	 		 		 	      Director, Technology Transfer &
         Intellectual Property Services

					
	Date:	 	2/14/02	 		 	Date:	 	Feb 4, 2002

  

			
		  	  
 ***Confidential Treatment
RequestedLicense Agreement

 Exhibit 10.17 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

LICENSE AGREEMENT 
 This License Agreement, effective upon the date of last signature herein (the “Effective Date”), by and between The Penn State Research Foundation (hereinafter referred to as “PSRF”),
a non-profit corporation duly organized and existing under the laws of the Commonwealth of Pennsylvania and having an office at 304 Old Main, University Park, PA 16802, and Genomatica, Inc., a corporation organized under the laws of the State of
California (hereinafter referred to as “LICENSEE”), having its principal office at 5405 Morehouse Drive, Suite 210, San Diego, CA 92121. 
 WITNESSETH 
 WHEREAS, [...***...], employees of The Pennsylvania
State University (the “UNIVERSITY”) have made an invention entitled “[...***...]”, filed as The Pennsylvania State University Invention Disclosure No. [...***...] (the “INVENTION”); 

WHEREAS, PSRF is dedicated to fostering and advancing scientific research within the Commonwealth of Pennsylvania and, in particular,
within the UNIVERSITY and is responsible for developing inventions made by employees of the UNIVERSITY by evaluating invention disclosures, pursuing patents, and pursuing licensing arrangements thereon; 

WHEREAS, PSRF is the owner of certain “PATENT RIGHTS” (as defined hereinbelow) relating to INVENTION and has the right to grant
licenses under PATENT RIGHTS; 
 NOW THEREFORE, in consideration of the mutual promises and covenants set forth herein and for
good and valuable consideration, the adequacy and sufficiency of which is hereby acknowledged, the parties hereby agree as follows: 
 ARTICLE 1  
 DEFINITIONS 

For purposes of this License Agreement, the following words and phrases shall have the following meanings: 

1.1 “AFFILIATES” shall mean any entity which directly or indirectly controls, is controlled by or is under common
control with Licensee. The term “control” as used herein means the possession of the power to direct or cause the direction of the management and the policies of an entity, whether through the ownership of a majority of the outstanding
voting securities or by contract or otherwise. 
 1.2 “LICENSEE” shall be Genomatica, Inc. and its Affiliates.

  

			
	1.	  	  
 ***Confidential Treatment
Requested

 1.3 “FIELD” shall mean the study and determination of optimal performance
characteristics of biochemical reaction and regulatory networks, including, [...***...]. 
 1.4
“TERRITORY” shall mean the world. 
 1.5 “PATENT RIGHTS” shall mean all of the following without
limitation: 
 (a) [...***...], together with all pending and issued U. S. and foreign counterparts of such
application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are
enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6 and; 

(b) [...***...], together with all pending and issued U. S. and foreign counterparts of such application filed and
prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of
the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6. 
 1.6 “LICENSED PRODUCT” shall mean any process, product or part thereof, or use or manufacture of a product or part thereof, which is covered in whole or in part by at least one unexpired
claim of PATENT RIGHTS in the country in which any such process, product or part thereof is made, used, or sold. 
 ARTICLE 2
 
 THE LICENSE 
 2.1 Subject to any preexisting rights, if any, of the Government of the United States created by the use of Government funding, PSRF hereby grants to LICENSEE an exclusive right and license in the
TERRITORY for the FIELD, with right to sublicense, to PATENTS RIGHTS and, to the extent not prohibited by other third party patents, to make, have made, use, lease, sell, have sold, offer for sale, and import LICENSED PRODUCTS for the term set forth
herein, unless this License Agreement shall be earlier terminated according to the terms and conditions contained herein. 

2.2 PSRF reserves the rights for itself and the UNIVERSITY [...***...]. 

2.3 LICENSEE agrees that LICENSED PRODUCTs leased or sold in the United States will be manufactured substantially in the United
States. 

  

			
	2.	  	  
 ***Confidential Treatment
Requested

 2.4 LICENSEE shall have the exclusive right, at its sole discretion, to sublicense
any of the rights, privileges and license granted hereunder during the term of this License Agreement. 
 2.5 The license
rights granted hereunder shall not be construed to confer any rights upon LICENSEE by implication, estoppel or otherwise to any technology owned or controlled by PSRF which is not specifically set forth herein. 

2.6 UNIVERSITY hereby grants to LICENSEE an exclusive option to acquire an exclusive, worldwide license (with the right to
sublicense) to develop, make, have made, use, sell, have sold, offer for sale and import products and employ methods covered by or incorporating any [...***...] invention in the FIELD discovered or reduced to practice by [...***...]
during the term of this Agreement (each, a “[...***...] Invention”). UNIVERSITY shall promptly notify LICENSEE in writing of any such [...***...] Invention. With respect to any specific [...***...] Invention, such option
shall extend for a period of [...***...] following the date of [...***...] in writing to LICENSEE by UNIVERSITY of [...***...] (the “Option Term”). The Option Term with respect to any particular [...***...]
Invention may be extended by mutual written agreement of UNIVERSITY and LICENSEE. UNIVERSITY agrees that, prior to and during the applicable Option Term, [...***...]. LICENSEE shall exercise its option hereunder by providing to UNIVERSITY
written notice of such exercise prior to the expiration of the applicable Option Term. Following receipt of such election notice, the parties shall commence in good faith negotiations on the terms of such license. Such license shall contain
commercially reasonable terms typically contained in license agreements pertaining to [...***...]. Any failure by LICENSEE to exercise its rights with respect to any particular [...***...] Invention shall not affect its rights under this
Section 2.6 or constitute a waiver of such rights with respect to any other [...***...] Invention. 
 ARTICLE 3 

 PAYMENTS 
 3.1 In partial consideration of the rights granted by this License Agreement, LICENSEE shall pay to PSRF a non-refundable, License Issue Fee of [...***...] upon execution of this License
Agreement. Said License Issue Fee shall be paid upon the Effective Date of this License Agreement. 
 3.2 LICENSEE shall
issue to UNIVERSITY [...***...] shares of Genomatica, Inc. common stock upon the filing of the U.S. Patent Application claiming priority to U.S. Provisional Patent Application No. [...***...]. UNIVERSITY shall file such patent
application on or before [...***...]. 
 3.3 LICENSEE shall issue to UNIVERSITY [...***...] shares of
Genomatica, Inc. common stock within [...***...] after the issue date of the first U.S. Patent included in the PATENT RIGHTS. 

  

			
	3.	  	  
 ***Confidential Treatment
Requested

 3.4 All monetary payments due hereunder are expressed in and shall be paid by check
payable in United States of America currency, without deduction of exchange, collection or other charges, to PSRF in University Park, PA or at such other place as PSRF may reasonably designate. 

3.5 For converting into United States dollars any payment accrued hereunder in the currency of any other country, the rate of
exchange for the purchase of United States dollars with such currency quoted by The Chase Manhattan Bank, New York, New York, on the last business day of the payment period in question shall be used. 

3.6 All stock issued will be Common Stock subject to the terms and conditions, and the representations and warranties contained in
the Investment Representation Letter attached hereto as Appendix A. PSRF’s ownership of Common Stock shall be as represented in the capitalization table attached as Appendix B. 

3.7 All payments set forth in this Agreement shall, if overdue, bear interest until payment at a per annum rate of
[...***...] on the due date. The payment of such interest shall not foreclose PSRF from exercising any other rights it may have as a consequence of the lateness of any payment. 

3.8 LICENSEE’s failure to make payments in accordance with Paragraphs 3.1, 3.2, or 3.3 shall constitute a material breach or
default and shall be grounds for termination of this License Agreement pursuant to Paragraph 13.3 hereof. 
 ARTICLE 4 

 MARKETING EFFORTS 
 4.1 LICENSEE shall use reasonable efforts to diligently bring one or more LICENSED PRODUCTS into the commercial market as soon as practicable and to continue active, diligent marketing efforts for
one or more LICENSED PRODUCTS throughout the term of this License Agreement. 
 4.2 LICENSEE’s failure to perform in
accordance with Paragraph 4.1 for a period of [...***...] upon written notice thereof to LICENSEE. 
 4.3 In
the event that LICENSEE in its sole discretion decides to market one or more LICENSED PRODUCTs in any country, then LICENSEE shall exert reasonable efforts to have such LICENSED PRODUCTs cleared for marketing by the responsible government agencies
of that country requiring such clearance. Should LICENSEE terminate this License Agreement, LICENSEE agrees to assign its full right, title, and interest in and to such market clearance application, including all data relating thereto, to PSRF
[...***...]. 

  

			
	4.	  	  
 ***Confidential Treatment
Requested

 ARTICLE 5  

PATENT PROSECUTION AND MAINTENANCE 
 5.1 Prosecution and Maintenance. PSRF shall apply for, seek prompt issuance of, and maintain the PATENT RIGHTS during the term of this Agreement. The prosecution, filing and maintenance of
patent applications and patents which issue therefrom shall be the primary responsibility of PSRF, or its designee, but wherever practical, LICENSEE shall be given the opportunity to review and comment upon the breadth and coverage of said patent
applications. During the patent preparation, prosecution and maintenance process, LICENSEE shall have reasonable opportunities to advise PSRF to ensure that said PATENT RIGHTS adequately address the commercial and business needs of LICENSEE.

 5.2 Cooperation of the Parties. Each party agrees to cooperate fully in the preparation, filing, and
prosecution of any PATENT RIGHTS under this Agreement. Such cooperation includes, but is not limited to: 
 (a) executing
all papers and instruments, or requiring its employees or agents, to execute such papers and instruments, so as to effectuate the ownership of INVENTIONS and PATENT RIGHTS, and to enable the other party to apply for and to prosecute patent
applications in any country; and 
 (b) promptly informing the other party of any matters coming to such party’s
attention that may affect the preparation, filing, or prosecution of any such patent applications. 
 5.3 U.S. Patent
Filings. LICENSEE shall reimburse PSRF for all reasonable and ordinary fees and external costs actually incurred in connection with the filing, prosecution, maintenance and defense of U.S. provisional and non-provisional patent applications and
resulting patents, pursuant to the conditions set forth herein. PSRF shall promptly provide copies of invoices for all such expenses and LICENSEE shall make payment thereof within thirty (30) days of receipt thereof. 

5.4 International Patent Filings. LICENSEE understands and agrees that the primary responsibility for the costs of all
foreign patent filings shall be LICENSEE’s, and that LICENSEE’s failure to timely communicate its decision regarding foreign filing and payment thereof may result in a loss of rights to LICENSEE. PSRF shall provide LICENSEE with all
information necessary for LICENSEE to establish relevant filing deadlines related to foreign patent applications. PSRF shall apply for, seek prompt issuance of, and maintain PATENT RIGHTS in those foreign jurisdictions designated by LICENSEE.
LICENSEE shall notify PSRF no later than three (3) months before applicable bar dates, as to the foreign countries in which it wishes PSRF to seek, or continue to seek, patent protection. Payment of all fees and costs relating to the
preparation, filing, prosecution and maintenance of said foreign PATENT RIGHTS shall be the direct responsibility of LICENSEE, provided LICENSEE is kept reasonably informed and given advance estimates where practical. If LICENSEE does not provide
payment of such fees and costs reasonably in advance of any applicable bar date, 

  

			
	5.	  	

 
LICENSEE agrees that said non-payment shall constitute a binding waiver of any right to obtain said foreign protection and LICENSEE holds PSRF harmless from any claim based thereon. 

5.5 Abandonment. In the event LICENSEE decides not to continue paying the fees and costs associated with the filing,
prosecution or maintenance of any PATENT RIGHTS, LICENSEE shall timely notify PSRF in writing in order that PSRF may continue said filing, prosecution or maintenance of such intellectual property at its own expense. LICENSEE’s right under this
License Agreement to any claims contained within the PATENT RIGHTS for any country in which LICENSEE does not continue paying the fees and costs associated with prosecution or maintenance in accordance with paragraph 5.1, 5.3 or 5.4 above shall
immediately terminate upon receipt of such notice, but only for the applicable country or countries. 
 5.6 Grounds
for Material Breach. Subject to Section 5.5, LICENSEE’s failure to make payments in accordance with Paragraph 5.3 and 5.4 shall constitute a material breach or default and shall be grounds for termination of this License Agreement
pursuant to Article XII hereof. 
 ARTICLE 6  

INFRINGEMENT AND OTHER ACTIONS 
 6.1 LICENSEE and PSRF shall promptly provide written notice, to the other party, of any alleged infringement by a third party of any patent licensed hereunder under PATENT RIGHTS and provide such
other party with any available evidence of such infringement. 
 6.2 Both parties shall use their best efforts in
cooperating with each other to terminate such infringement without litigation. For so long as [...***...] shall have the first right, but not the obligation, at its cost and expense, to bring and control any action or proceeding with respect
to such infringement of PATENT RIGHTS by a third party (or any declaratory judgment action alleging invalidity or noninfringement of any of the PATENT RIGHTS) with counsel of its own choice, and [...***...] may, for such purposes, join
[...***...] as a party plaintiff. [...***...] shall have the right, at its own expense, to be represented in any such action with counsel of its own choice. If [...***...] fails to bring an action or proceeding [...***...]
shall have the right, but not the obligation, to bring and control any such action at its own expense and by counsel of its own choice, and [...***...] shall have the right, at its own expense, to be represented in any such action by counsel
of its own choice. In the event a party brings an infringement action, the other party shall cooperate fully, including if required to bring such action, the furnishing of a power of attorney. Neither party shall have the right to settle any patent
infringement litigation under this Section 6.2 in a manner that diminishes the rights or interests of the other party without the prior written consent of such other party. Except as otherwise agreed to by the parties as part of a cost-sharing
arrangement, any recovery realized as a result of such litigation, after reimbursement of any litigation expenses shall be retained by the party bringing such action. 

  

			
	6.	  	  
 ***Confidential Treatment
Requested

 6.3 [...***...] shall have the first right to control any defense of any claim
involving alleged infringement of third party rights by the PATENT RIGHTS or [...***...], at its own expense and by counsel of its own choice, and [...***...] shall have the right, at its own expense, to be represented in any such action
by counsel of its own choice. [...***...] shall have the right to control any such defense of such claim at its own expense and by counsel of its own choice, and [...***...] shall have the right, at its own expense, to be represented in
any such action by counsel of its own choice. Neither party shall have the right to settle any patent infringement litigation under this Section 6.3 in a manner that diminishes the rights or interests of the other party without the consent of
such other party. 
 6.4 LICENSEE, during the exclusive period of this License Agreement, shall have the
[...***...] rights in accordance with the terms and conditions herein to sublicense any alleged infringer in the TERRITORY for the FIELD for future use of the PATENT RIGHTS. 

ARTICLE 7  
 INDEMNIFICATION 
 7.1 LICENSEE shall at all times during the
term of this License Agreement and thereafter, indemnify, defend and hold PSRF, its trustees, directors, officers, employees and affiliates, harmless against all claims, proceedings, demands and liabilities of any kind whatsoever, [...***...].

 7.2 [...***...], LICENSEE shall obtain and carry in full force and effect commercial, general liability
insurance which shall protect LICENSEE and PSRF with respect to events covered by Paragraph 7.1 above. Such insurance shall be written by a reputable insurance company authorized to do business in the Commonwealth of Pennsylvania, shall list
PSRF as an additional named insured thereunder, shall be endorsed to include product liability coverage and shall require [...***...] written notice to be given to PSRF prior to any cancellation or material change thereof. The limits of such
insurance shall not be less than [...***...] per occurrence with an aggregate of [...***...] for personal injury or death, and [...***...] per occurrence with an aggregate of [...***...] for property damage. LICENSEE shall
provide PSRF with Certificates of Insurance evidencing the same. 
 7.3 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS
LICENSE AGREEMENT, PSRF, ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AND AFFILIATES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO

  

			
	7.	  	  
 ***Confidential Treatment
Requested

 
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE.
NOTHING IN THIS LICENSE AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY PSRF THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. IN NO EVENT SHALL PSRF,
ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES OR LICENSEE, ITS DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST
PROFITS, REGARDLESS OF WHETHER ANY SUCH PARTY SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY. 
 ARTICLE 8  
 EXPORT CONTROLS 

8.1 It is understood that PSRF is subject to United States laws and regulations controlling the export of technical data, computer
software, laboratory prototypes and other commodities (including the Arms Export Control Act, as amended and the Export Administration Act of 1979), and that its obligations hereunder are contingent on compliance with applicable United States export
laws and regulations. The transfer of certain technical data and commodities may require a license from the cognizant agency of the United States Government and/or written assurances by LICENSEE that LICENSEE shall not export data or commodities to
certain foreign countries without prior approval of such agency. PSRF neither represents that a license shall not be required nor that, if required, it shall be issued. 
 ARTICLE 9  
 NON-USE OF NAMES 

9.1 LICENSEE shall not use the names or trademarks of Penn State, PSRF, or any of their employees, or any adaptation thereof, in
any advertising, promotional or sales literature without prior written consent obtained from PSRF, in each case, except that LICENSEE may, without prior written consent, state that it is licensed by PSRF, under one or more of the patents and/or
applications comprising the PATENT RIGHTS. 
 ARTICLE 10  

PAYMENTS, NOTICES AND OTHER COMMUNICATIONS 
 10.1 Any payment, notice or other communication pursuant to this License Agreement shall be sufficiently made or given on the date of mailing if sent to such party by certified or registered first
class mail, postage prepaid, addressed to it at its address below or as it shall designate by written notice given to the other party as follows: 

  

			
	8.	  	

	
	In the case of THE PENN STATE RESEARCH FOUNDATION:
	  
 President

	 The Penn State Research Foundation

	 c/o Intellectual Property Office

	 113 Technology Center

	 University Park, PA 16802-7000

	  
 In the case of LICENSEE:

	  
 Thomas A. Reed

	 Vice President Finance and Corporate Development

	 Genomatica, Inc.

	 5405 Morehouse Drive

	 Suite 210

	 San Diego, CA 92121

 ARTICLE 11  
 ASSIGNMENT 
 11.1 This License Agreement shall not be
assignable by either party without the prior written consent of the other party except to a successor in ownership of all or substantially all of the business assets of a party hereto related to this Agreement, and which successor shall expressly
assume in writing the performance of all the terms and conditions of this License Agreement to be performed by the assigning party. 
 ARTICLE 12  
 DISPUTE RESOLUTION 

12.1 Except for the right of either party to apply to a court of competent jurisdiction for a temporary restraining order, a
preliminary injunction, or other equitable relief to preserve the status quo or prevent irreparable harm, any and all claims, disputes or controversies arising under, out of, or in connection with this License Agreement, including any dispute
relating to patent validity or infringement, which the parties shall be unable to resolve within [...***...], shall be mediated in good faith. The party raising such dispute shall promptly advise the other party of such claim, dispute or
controversy in a writing which describes in reasonable detail the nature of such dispute. By not later than [...***...] after the recipient has received such notice of dispute, each party shall have selected for itself a representative who
shall have the authority to bind such party, and shall additionally have advised the other party in writing of the name and title of such representative. By not later than [...***...] after the date of such notice of dispute, the party against
whom the dispute shall be raised shall select a mediation firm [...***...] and such representatives shall schedule a date with such firm for a mediation hearing. The parties shall enter into good faith mediation [...***...]. If the
representatives of the parties have not been able to resolve the dispute within [...***...] after such mediation hearing, the parties shall have the 

  

			
	9.	  	  
 ***Confidential Treatment
Requested

 
right to pursue any other remedies legally available to resolve such dispute in [...***...], to whose jurisdiction for such purposes PSRF and LICENSEE each hereby irrevocably consents and
submits. 
 12.2 Notwithstanding the foregoing, nothing in this Article XII shall be construed to waive any rights or
timely performance of any obligations existing under this License Agreement. 
 ARTICLE 13  

TERM AND TERMINATION 
 13.1 LICENSEE shall have the right to terminate this Agreement at any time on six (6) months’ notice to PSRF, and upon payment of all amounts due PSRF through the effective date of the
termination. 
 13.2 Financial Solvency of LICENSEE. LICENSEE agrees that as a part of its material inducement to
PSRF to enter this License Agreement, it shall provide PSRF with at least ninety (90) days written notice hereunder of its intent to file a petition in Bankruptcy, whether it be for a Chapter 7, 11, 13 or any other such petition. LICENSEE
agrees and understands that PSRF has an obligation to University, a land grant institution under the Morrell Act, to license the PATENT RIGHTS pursuant to terms and conditions which maximize the public benefit. PSRF shall have the right to
immediately terminate this License Agreement by giving written notice to LICENSEE, in the event LICENSEE does any of the following: a) provides notice hereunder of its intent to file (or does actually file without providing said notice) a petition
in bankruptcy, b) attempts to make an assignment hereof for the benefit of creditors, c) discontinues or dissolves its business, or d) if a receiver is appointed for LICENSEE. 
 13.3 Financial Breach. In the event LICENSEE has breached its obligations to pay fees or equity under Article III of this License Agreement, (hereafter “Financial Breach”) PSRF
shall provide LICENSEE with written notice of said breach, and LICENSEE shall have a period of thirty (30) days to cure said breach. In the event LICENSEE does not fully cure the breach within that thirty (30) day period, and fails within
that thirty (30) days to commence mediation pursuant to Article XII of this License Agreement alleging grounds for its non-payment thereof, this License Agreement shall be automatically terminated without further notice or action by PSRF.
Notwithstanding LICENSEE’s rights to cure herein, in the event LICENSEE [...***...], PSRF shall be entitled to give notice of breach which shall become effective immediately upon LICENSEE’s receipt of said Notice, and for which
LICENSEE shall not have any further right of “cure.” 
 13.4 Failure of Other Performance. Upon any
material breach of performance under this License Agreement, by LICENSEE, other than those occurrences set out in Paragraphs 13.2 or 13.3 hereinabove, which shall always take precedence in that order over any material breach or default referred to
in this Paragraph 13.4, PSRF shall have the right to terminate this License Agreement and the rights, privileges and license granted hereunder effective sixty (60) days after 

  

			
	10.	  	  
 ***Confidential Treatment
Requested

 
PSRF first notifies LICENSEE of the alleged breach under the notice provisions contained in Article X of this License Agreement. As used in this License Agreement, the term “Material
Breach of Performance” shall include, but not be limited to the following: [...***...]. Such termination shall become effective upon final notification by PSRF after the sixty (60) days, unless LICENSEE shall have fully cured any
such material breach or default prior to the expiration of the sixty (60) day period. In the event of a dispute as to whether LICENSEE has cured the alleged breach, the matter shall be resolved pursuant to Article XII of this License Agreement.

 13.5 Upon termination of this License Agreement for any reason, nothing herein shall be construed to release either
party from any obligation that matured prior to the effective date of such termination; and Articles I, VII, VIII, IX, XIV and paragraphs 13.5 and 13.6 shall survive any such termination. LICENSEE and any sublicensee thereof may, however, after the
effective date of such termination, sell all LICENSED PRODUCTs, and complete LICENSED PRODUCTs in the process of manufacture at the time of such termination and sell the same. 
 13.6 Upon termination of this Agreement for any reason, any sublicensee not then in default shall have the right to seek a license from PSRF. PSRF agrees to negotiate such licenses in good faith
under reasonable terms and conditions; provided, however, that LICENSEE may submit a proposed sublicense to PSRF in advance for PSRF’s prior approval, such approval not to be unreasonably withheld or delayed (i.e. PSRF will respond within
forty-five (45) days after receipt of such proposal from LICENSEE), and if PSRF approves such sublicense, then such sublicense shall also become a direct license between the sublicensee and PSRF upon termination of this Agreement for any
reason, provided that such sublicensee is not the cause of the termination of this Agreement. 
 ARTICLE 14 

MISCELLANEOUS PROVISIONS 
 14.1 Entire Agreement. This License Agreement embodies the entire understanding of the parties and shall supersede all previous communications, representations, or undertakings, either
verbal or written, between the parties relating to the subject matter hereof. 
 14.2 Amendment. This License
Agreement may be amended only by a written agreement embodying the full terms of the amendment signed by authorized representatives of both parties. 
 14.3 Severability. Should any provision of this License Agreement be held to be illegal, invalid or unenforceable, by any court of competent jurisdiction, such provision shall be modified by
such court in compliance with the law and, as modified, enforced. The remaining provisions of this License Agreement shall be construed in accordance with the modified provision and as if such illegal, invalid or unenforceable provision had not been
contained herein. 

  

			
	11.	  	  
 ***Confidential Treatment
Requested

 14.4 No Strict Construction. The language used in this License Agreement shall
be deemed to be the language chosen by both parties hereto to express their mutual intent and no rule of strict construction against either party shall apply to any term or condition of this License Agreement. 

14.5 Relationship of Parties. Nothing contained in this License Agreement shall be construed as creating a partnership,
joint venture, agency or an association of any kind. 
 14.6 No Waiver. The failure of one party hereto to enforce
at any time any of the provisions of this License Agreement, or any rights in respect thereto, or to exercise any election herein provided, shall in no way be considered to be a waiver of such provision, rights or elections or in any way to affect
the validity of this License Agreement, or excuse a similar subsequent failure to perform any such term or condition by the other party. Any waiver must be in writing. 
 14.7 Interpretation. The headings of several sections contained herein are inserted for convenience of reference only, and are not intended to be a part of or to affect the meaning or
interpretation of this License Agreement. 
 14.8 Governing Law. This License Agreement shall be governed by and
construed in accordance with the laws of [...***...] without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than [...***...], except that
questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent was granted. 
 14.9 Product Marking. LICENSEE agrees to mark the LICENSED PRODUCTs sold in the United States with all applicable United States patent numbers. All LICENSED PRODUCTs shipped to or sold in
other countries shall be marked in such a manner as to conform with the patent laws and practices of the country of manufacture or sale. 
 14.10 Counterparts. This Agreement may be signed in one or more counterparts, by facsimile, or both, each of which will be considered an original, all of which will constitute the same
instrument. 

  

			
	12.	  	  
 ***Confidential Treatment
Requested

 IN WITNESS WHEREOF, the parties hereto, intending to be legally bound hereby, have each
caused a duly authorized representative to execute this License Agreement on the day and year set forth below. 
  

			
	GENOMATICA, INC.
	
	(LICENSEE)
		
	By:	 	 /s/ Bernhard Palsson

		
	Name:	 	 Bernhard Palsson

		
	Title:	 	 Chief Executive Officer

		
	Date:	 	 December 20, 2001

  

			
	THE PENN STATE RESEARCH FOUNDATION
		
	 (PSRF)
	 	
		
	By:	 	 /s/ David E. Branigan

		
	Name:	 	 David E. Branigan

		
	Title:	 	 Treasurer

		
	Date:	 	 February 12, 2002

 APPENDIX A 
 January 9, 2002 
 Genomatica, Inc. 
 5405 Morehouse Drive 
 Suite 210 
 San Diego, CA 92121 
 Ladies and Gentlemen: 

The undersigned hereby makes the following certifications and representations with respect to the [...***...] shares (the “Shares”) of
Common Stock of GENOMATICA, INC., a California corporation (the “Company”), which are being acquired by the undersigned pursuant to the License Agreement by and between the Company and the undersigned.

 The undersigned represents and warrants that it is acquiring said shares solely for its account for investment and not with a view to or for
sale or distribution of said shares or any part thereof. The undersigned also represents that the entire legal and beneficial interests of the shares the undersigned is acquiring is being acquired for, and will be held for, its account only.

 The undersigned understands that[ the shares have not been registered under the Securities Act of 1933, as amended (the “Act”), on
the basis that no distribution or public offering of the shares is to be effected. The undersigned realizes that the basis for the exemption may not be present if, notwithstanding its representations, it has in mind merely acquiring the securities
for a fixed or determinable period in the future, or for a market rise, or for sale if the market does not rise. The undersigned has no such intention. 
 The undersigned recognizes that the shares being acquired by it must be held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The
undersigned recognizes that the Company has no obligation to register the shares or to comply with any exemption from such registration. 
 The
undersigned is aware that [the shares may not be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met and until the undersigned has held the shares for at least one year. Among the conditions for use of the Rule is the
availability of current information to the public about the Company. The undersigned understands that the Company has not made such information available and has no present plans to do so. 
 The undersigned further agrees not to make any disposition of all or any part of the shares being acquired in any event unless and until: 

1. The Company shall have received a letter secured by the undersigned from the Securities and Exchange Commission stating
that no action will be recommended to the Commission with respect to the proposed disposition; or 

  

			
		  	  
 ***Confidential Treatment
Requested

 2. There is then in effect a registration statement under the Act covering
such proposed disposition and such disposition is made in accordance with said registration statement; or 
 3.
(i) The undersigned shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, (ii) the undersigned shall have furnished
the Company with an opinion of counsel for the undersigned to the effect that such disposition will not require registration of such shares under the Act, and (iii) such opinion of counsel for the undersigned shall have been concurred in by the
Company’s counsel and the Company shall have advised the undersigned of such concurrence. 
 If requested by the Company and an underwriter
of Common Stock (or other securities) of the Company, the undersigned shall not sell or otherwise transfer or dispose of any Shares (or other securities) of the Company then owned by the undersigned (other than those included in such registration)
during the one hundred eighty (180) day period (or such lessor period as is permitted by the underwriter) following the effective date of a registration statement of the Company filed under the Securities Act. 

The undersigned understands and agrees that all certificates evidencing the shares to be issued to the undersigned may bear the following legends:

 “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED
FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.” 

“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL OPTION IN FAVOR OF THE COMPANY AND/OR ITS
ASSIGNEE(S), AS PROVIDED IN THE BYLAWS OF THE COMPANY.” 
 Very truly yours, 

 

			
	THE PENN STATE RESEARCH FOUNDATION
		
	By:	 	 /s/ David E. Branigan

		
	Name:	 	 David E. Branigan

		
	Title:	 	 Treasurer

 ADDENDUM TO THE LICENSE AGREEMENT 

This Addendum (hereinafter referred to as the “Addendum”), effective on June 26, 2003 (hereinafter the “Effective
Date”), is by and between the PENN STATE RESEARCH FOUNDATION, a non-profit corporation duly organized and existing under the laws of the Commonwealth of Pennsylvania and having an office at 304 Old Main, University Park, Pennsylvania 16802
(hereinafter referred to as “PSRF”), and Genomatica, Inc., a corporation organized under the laws of California (hereinafter referred to as “LICENSEE”), having its principal office at 5405 Morehouse Drive, Suite 210, San Diego,
CA 92121. All capitalized terms not otherwise defined herein shall have the meanings given to them in the License Agreement (as defined below). 
 WHEREAS, PSRF and LICENSEE entered into a License Agreement (the “License Agreement”), effective February 12, 2002, whereby PSRF granted LICENSEE an exclusive right and license in the
Territory for the Field, with the right to sublicense, to Patent Rights and to make, have made, use, lease, sell, have sold, offer for sale, and import Licensed Products; 
 WHEREAS, pursuant to Paragraph 2.6 of the License Agreement, LICENSEE has the option to acquire an exclusive, worldwide license to certain inventions related to the rights obtained under the License
Agreement; 
 WHEREAS, [...***...], employees of The Pennsylvania State University (hereinafter referred to as
“UNIVERSITY”), have invented [...***...]; 
 WHEREAS, PSRF has informed LICENSEE [...***...], as required
under Paragraph 2.6 of the License Agreement; 
 WHEREAS, PSRF is the owner of patent rights relating to [...***...] and
has the right to grant licenses under such patent rights; 
 WHEREAS, LICENSEE has represented that it wishes to obtain
exclusive rights to [...***...]; and 
 WHEREAS, PSRF desires to have [...***...] utilized in the public interest
and is willing to grant a license to PSRF’s rights hereunder. 
 Now, therefore, and in consideration for the foregoing and
the covenants and promises hereinafter set forth, the parties hereto agree as follows: 
 1. Paragraph 1.5 of the License Agreement is replaced
in its entirety as follows: 
 1.5 “PATENT RIGHTS” shall mean all of the following without limitation; 

(a) [...***...], together with all pending and issued U.S. and foreign counterparts of such application filed and prosecuted
pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, 

  

			
		  	***Confidential Treatment Requested

 
continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or
foreign counterparts filed and prosecuted pursuant to Article 6 and; 
 (b) [...***...], together with all pending and
issued U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but
only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6 and; 

(c) [...***...], together with all pending and issued U.S. and foreign counterparts of such application filed and prosecuted
pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent
application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6 and; 
 (d) [...***...], together with all pending and issued U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing
therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or
reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6 and; 
 (e) [...***...],
together with all pending and issued U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations,
continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and
prosecuted pursuant to Article 6. 
 2. Paragraph 3.6 of the License Agreement is replaced in its entirety as follows: 

3.6 All stock issued will be Common Stock subject to the terms and conditions, and the representations and warranties contained in the
Investment Representation Letters attached hereto as Appendix A and Appendix A-1, as applicable. PSRF’s ownership of Common Stock shall be as represented in the capitalization table attached as Appendix B. 

3. Paragraph 3.9 is added to the License Agreement as follows: 

  

			
		  	***Confidential Treatment Requested

 3.9 LICENSEE shall issue to UNIVERSITY [...***...] shares of Genomatica, Inc. common
stock upon the filing of the U.S. Patent Application or counterpart PCT application claiming priority to U.S. Provisional Patent Application [...***...]. UNIVERSITY shall file such patent application on or before [...***...]. 

4. Appendix A-1 hereto is added to the License Agreement. 
 5. Appendix B to the License Agreement is replaced with Appendix B hereto. 
 6. PSRF has
sufficient rights and power to grant the license to LICENSEE which it purports to grant by this Addendum. 
 7. Except as specifically set forth
by this Addendum, the terms and conditions of the License Agreement shall remain in full force and effect. This Addendum may be executed in two counterparts, each of which shall be deemed an original, but both of which together shall constitute one
and the same instrument. 

  

			
		  	***Confidential Treatment Requested

 IN WITNESS WHEREOF, the parties hereto have executed this Addendum, in duplicate, by proper
persons thereunto duly authorized. 
  

			
	PENN STATE RESEARCH FOUNDATION
		
	By:	 	 /s/ David E. Branigan

		
	Name:	 	 David E. Branigan

		
	Title:	 	 Treasurer

		
	Date:	 	 July 11, 2003

  

			
	GENOMATICA, INC.
		
	By:	 	 /s/ Christophe Schilling

		
	Name:	 	 Christophe Schilling

		
	Title:	 	 V.P. & Chief Technical Officer

		
	Date:	 	 July 8, 2003

 Appendix A-1 
 June 26, 2003 
 Genomatica, Inc. 
 5405 Morehouse Drive 
 Suite 210 
 San Diego, CA 92121 
 Ladies and Gentlemen: 

The undersigned hereby makes the following certifications and representations with respect to the [...***...] shares (the “Shares”) of
Common Stock of GENOMATICA, INC., a California corporation (the “Company”), which are being acquired by the undersigned pursuant to the License Agreement (including the Addendum thereto) by and between the
Company and the undersigned. 
 The undersigned represents and warrants that it is acquiring said shares solely for its account for investment
and not with a view to or for sale or distribution of said shares or any part thereof. The undersigned also represents that the entire legal and beneficial interests of the shares the undersigned is acquiring is being acquired for, and will be held
for, its account only. 
 The undersigned understands that the shares have not been registered under the Securities Act of 1933, as amended (the
“Act”), on the basis that no distribution or public offering of the shares is to be effected. The undersigned realizes that the basis for the exemption may not be present if, notwithstanding its representations, it has in mind merely
acquiring the securities for a fixed or determinable period in the future, or for a market rise, or for sale if the market does not rise. The undersigned has no such intention. 
 The undersigned recognizes that the shares being acquired by it must be held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The
undersigned recognizes that the Company has no obligation to register the shares or to comply with any exemption from such registration. 
 The
undersigned is aware that the shares may not be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met and until the undersigned has held the shares for at least one year. Among the conditions for use of the Rule is the
availability of current information to the public about the Company. The undersigned understands that the Company has not made such information available and has no present plans to do so. 
 The undersigned further agrees not to make any disposition of all or any part of the shares being acquired in any event unless and until: 

 

	1.	The Company shall have received a letter secured by the undersigned from the Securities and Exchange Commission stating that no action will be recommended to the
Commission with respect to the proposed disposition; or 

	2.	There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with said registration
statement; or 

  

	3.	(i) The undersigned shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances
surrounding the proposed disposition, (ii) the undersigned shall have furnished the Company with an opinion of counsel for the undersigned to the effect that such disposition will not require registration of such shares under the Act, and
(iii) such opinion of counsel for the undersigned shall have been concurred in by the Company’s counsel and the Company shall have advised the undersigned of such concurrence. 

If requested by the Company and an underwriter of Common Stock (or other securities) of the Company, the undersigned shall not sell or otherwise transfer
or dispose of any Shares (or other securities) of the Company then owned by the undersigned (other than those included in such registration) during the one hundred eighty (180) day period (or such lessor period as is permitted by the
underwriter) following the effective date of a registration statement of the Company filed under the Act. 
 The undersigned
understands and agrees that all certificates evidencing the shares to be issued to the undersigned may bear the following legends: 
 “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.” 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL OPTION IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S), AS PROVIDED IN THE BYLAWS OF THE COMPANY.” 

Very truly yours, 
  

			
	THE PENN STATE RESEARCH FOUNDATION
		
	By:	 	 /s/ David E. Branigan

		
	Name:	 	 David E. Branigan

		
	Title:	 	 Treasurer

		
	Date:	 	July 11, 2003

 Appendix B 
 [...***...] 

  

			
		  	***Confidential Treatment Requested

			
	 The Penn State

Research Foundation
  
	  	  
 The Pennsylvania State University
 304 Old Main

University Park, PA 16802-1504

814-865-6331
 814-863-9659 (fax)

 

 April 15, 2005

 Christophe H. Schilling, Ph.D. 

President & CSO 
 GENOMATICA, INC.

 5405 Morehouse Drive, Suite 210 
 San
Diego, CA 92121 
  

	RE:	February 12, 2002 License Agreement between Genomatica, Inc. and The Penn State Research Foundation (“PSRF”) 

Dear Dr. Schilling: 
 We
have reviewed your April 5, 2005 email correspondence and are in agreement with your suggested revision to the following amendment to Section 2.6. 
 2.6 UNIVERSITY hereby grants to LICENSEE an exclusive option to acquire an exclusive, worldwide license (with the right to sublicense) to develop, make, have made, use, sell, have sold, offer for sale and
import products and employ methods covered by or incorporating any [...***...] invention, [...***...] during the term of this Agreement (each, a “[...***...] Invention”). UNIVERSITY shall promptly notify LICENSEE in
writing of any such [...***...] Invention. With respect to any specific [...***...] Invention, such option shall extend for a period of [...***...] following the date of [...***...] in writing to LICENSEE by UNIVERSITY of
[...***...] (the “Option Term”). The Option Term with respect to any particular [...***...] Invention may be extended by mutual written agreement of UNIVERSITY and LICENSEE. UNIVERSITY agrees that, prior to and during the
applicable Option Term, it shall [...***...]. LICENSEE shall exercise its option hereunder by providing to UNIVERSITY written notice of such exercise prior to the expiration of the applicable Option Term. Following receipt of such election
notice, the parties shall commence in good faith negotiations on the terms of such license. Such license shall contain commercially reasonable terms typically contained in license agreements pertaining to [...***...]. Any failure by LICENSEE
to exercise its rights with respect to any particular [...***...] Invention shall not affect its rights under this Section 2.6 or constitute a waiver of such rights with respect to any other [...***...] Invention. 

 

	
	The Penn State Research Foundation is a nonprofit organization dedicated to fostering and advancing scientific research within
the
Commonwealth of Pennsylvania and to supporting the development of inventions at The Pennsylvania State University.

  

			
		  	***Confidential Treatment Requested

 Dr. Christophe H. Schilling 
 Page Two 
 April 15, 2005 

Except as specifically set forth by this Letter Agreement, the terms and conditions of the February 12, 2002 License Agreement
between Genomatica, Inc. and PSRF and the corresponding June 26, 2003 Addendum to the License Agreement shall apply. 
 If
such conditions are acceptable, please execute the two (2) originals of this letter agreement and return the two (2) originals of this letter agreement to me, so that I may process them for signature on behalf of The Penn State Research
Foundation. I will then return one (1) fully executed original to you. 
  

	
	 Sincerely,
  

/s/ [...***...]
 [...***...]
 [...***...]

  

			
	PENN STATE RESEARCH FOUNDATION
		
	By:	 	 /s/ David E. Branigan

		
	Name:	 	 David E. Branigan

		
	Title:	 	 Treasurer

		
	Date:	 	 April 19, 2005

  

			
	GENOMATICA, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

		
	Date:	 	  

 SECOND ADDENDUM TO THE LICENSE AGREEMENT 

This Second Addendum (hereinafter referred to as the “Addendum”), effective on May 17, 2005 (hereinafter the
“Effective Date”), is by and between the PENN STATE RESEARCH FOUNDATION, a non-profit corporation duly organized and existing under the laws of the Commonwealth of Pennsylvania and having an office at 304 Old Main, University Park,
Pennsylvania 16802 (hereinafter referred to as “PSRF”), and Genomatica, Inc., a corporation organized under the laws of California (hereinafter referred to as “LICENSEE”), having its principal office at 5405 Morehouse Drive,
Suite 210, San Diego, CA 92121. All capitalized terms not otherwise defined herein shall have the meanings given to them in the License Agreement (as defined below). 
 WHEREAS, PSRF and LICENSEE entered into a License Agreement (the “License Agreement”), effective February 12, 2002 and amended pursuant to that certain Addendum between the parties dated
June 26, 2003, whereby PSRF granted LICENSEE an exclusive right and license in the Territory for the Field, with the right to sublicense, to Patent Rights and to make, have made, use, lease, sell, have sold, offer for sale, and import Licensed
Products; 
 WHEREAS, pursuant to Paragraph 2.6 of the License Agreement, LICENSEE has the option to acquire an exclusive,
worldwide license to certain inventions related to the rights obtained under the License Agreement; 
 WHEREAS,
[...***...], employees of The Pennsylvania State University (hereinafter referred to as “UNIVERSITY”), have invented (1) [...***...] (PSU Invention Disclosure No. [...***...]) (hereinafter referred to as the
“[...***...]”) and (2) [...***...] (PSU Invention Disclosure No. [...***...]); 
 WHEREAS, PSRF
has informed LICENSEE of the [...***...] and the [...***...], as required under Paragraph 2.6 of the License Agreement; 
 WHEREAS, PSRF is the owner of patent rights relating to the [...***...]; 

WHEREAS, LICENSEE has represented that it wishes to obtain [...***...]; 

WHEREAS, PSRF desires to have the [...***...] utilized in the public interest and is willing to grant [...***...];

 WHEREAS, PSRF and LICENSEE wish to amend Paragraph 2.6 of the License Agreement [...***...]. 

Now, therefore, and in consideration for the foregoing and the covenants and promises hereinafter set forth, the parties hereto agree as
follows: 
 1. Paragraph 1.5 of the License Agreement is replaced in its entirety as follows: 

  

			
		  	***Confidential Treatment Requested

 1.5 “PATENT RIGHTS” shall mean all of the following without limitation;

 (a) [...***...], together with all pending and issued U.S. and foreign counterparts of such application filed and
prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of
the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6 and; 
 (b) [...***...], together with all pending and issued U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing
therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or
reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6 and; 
 (c) [...***...],
together with all pending and issued U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations,
continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and
prosecuted pursuant to Article 6 and; 
 (d) [...***...], together with all pending and issued U.S. and foreign
counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the extent the
claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6; 

(e) [...***...], together with all pending and issued U.S. and foreign counterparts of such application filed and prosecuted
pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals, re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent
application), divisions, substitute applications, and/or reissues of such application or foreign counterparts filed and prosecuted pursuant to Article 6; 
 (f) [...***...], together with all pending and issued 

  

			
		  	***Confidential Treatment Requested

 
U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals,
re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts
filed and prosecuted pursuant to Article 6; and 
 (g) Any patent application of any kind or type filed with respect to
[...***...], together with all pending and issued U.S. and foreign counterparts of such application filed and prosecuted pursuant to Article 6; and all U.S. and foreign patents issuing therefrom; and all pending and issued renewals,
re-examinations, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent application), divisions, substitute applications, and/or reissues of such application or foreign counterparts
filed and prosecuted pursuant to Article 6. 
 2. Paragraph 2.6 of the License Agreement is replaced in its entirety as follows: 

“2.6 UNIVERSITY hereby grants to LICENSEE [...***...] to develop, make, have made, use, sell, have sold, offer for sale and
import products and employ methods covered by or incorporating any [...***...] invention, [...***...] during the term of this Agreement (each, a “[...***...] Invention”). UNIVERSITY shall promptly notify LICENSEE in
writing of any such [...***...] Invention. With respect to any specific [...***...] Invention, such option shall extend for a period of [...***...] following the date of [...***...] in writing to LICENSEE by UNIVERSITY of
[...***...] (the “Option Term”). The Option Term with respect to any particular [...***...] Invention may be extended by mutual written agreement of UNIVERSITY and LICENSEE. UNIVERSITY agrees that, prior to and during the
applicable Option Term, [...***...]. LICENSEE shall exercise its option hereunder by providing to UNIVERSITY written notice of such exercise prior to the expiration of the applicable Option Term. Following receipt of such election notice, the
parties shall commence in good faith negotiations on the terms of such license. Such license shall contain commercially reasonable terms typically contained in license agreements pertaining to [...***...]. Any failure by LICENSEE to exercise
its rights with respect to any particular [...***...] Invention shall not affect its rights under this Section 2.6 or constitute a waiver of such rights with respect to any other [...***...] Invention.” 

Notwithstanding the foregoing, for purposes of clarification, the replacement of Section 2.6 pursuant to this Addendum shall apply to
[...***...] Inventions (as defined in the License Agreement) made after the date of this Addendum. The language in Section 2.6 as it existed prior to the date of this Addendum shall apply to all [...***...] Inventions that were
[...***...] prior to the date of this Addendum. 

  

			
		  	***Confidential Treatment Requested

 3. Paragraph 3.6 of the License Agreement is replaced in its entirety as follows: 

“3.6 All stock issued will be Common Stock subject to the terms and conditions, and the representations and warranties contained in
the Investment Representation Letters attached hereto as Appendix A. 
 4. Paragraph 3.10 is added to the License Agreement as follows:

 “3.10 LICENSEE shall issue to UNIVERSITY [...***...] shares of Genomatica, Inc. common stock (the
“[...***...]”) concurrent with the execution of this Addendum. [...***...]. [...***...] and all rights and interest therein or related thereto, and LICENSEE shall have the right to transfer to its own name the
[...***...] being repurchased by the Company, without further action by Purchaser.” 
 5. PSRF has sufficient rights and power to
grant the license to LICENSEE which it purports to grant by this Addendum. 
 6. Except as specifically set forth by this Addendum, the terms
and conditions of the License Agreement shall remain in full force and effect. This Addendum may be executed in two counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.

  

			
		  	***Confidential Treatment Requested

 IN WITNESS WHEREOF, the parties hereto have executed this Addendum, in duplicate, by proper
persons thereunto duly authorized. 
  

			
	PENN STATE RESEARCH FOUNDATION
		
	By:	 	 /s/ David E. Branigan

		
	Name:	 	 David E. Branigan

		
	Title:	 	 Treasurer

		
	Date:	 	 June 24, 2005

  

			
	GENOMATICA, INC.
		
	By:	 	 /s/ Thomas A. Reed

		
	Name:	 	 Thomas A. Reed

		
	Title:	 	 CFO

		
	Date:	 	 6/22/05

  

			
		  	***Confidential Treatment Requested

 Appendix A 
 June 24, 2005 
 Genomatica, Inc. 
 5405 Morehouse Drive 
 Suite 210 
 San Diego, CA 92121 
 Ladies and Gentlemen: 

The undersigned hereby makes the following certifications and representations with respect to the [...***...] shares (the “Shares”) of
Common Stock of GENOMATICA, INC., a California corporation (the “Company”), which are being acquired by the undersigned pursuant to the License Agreement (including the Second Addendum thereto) by and between
the Company and the undersigned. 
 The undersigned represents and warrants that it is acquiring said shares solely for its account for
investment and not with a view to or for sale or distribution of said shares or any part thereof. The undersigned also represents that the entire legal and beneficial interests of the shares the undersigned is acquiring is being acquired for, and
will be held for, its account only. 
 The undersigned understands that the shares have not been registered under the Securities Act of 1933, as
amended (the “Act”), on the basis that no distribution or public offering of the shares is to be effected. The undersigned realizes that the basis for the exemption may not be present if, notwithstanding its representations, it has in mind
merely acquiring the securities for a fixed or determinable period in the future, or for a market rise, or for sale if the market does not rise. The undersigned has no such intention. 
 The undersigned recognizes that the shares being acquired by it must be held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The
undersigned recognizes that the Company has no obligation to register the shares or to comply with any exemption from such registration. 
 The
undersigned is aware that the shares may not be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met and until the undersigned has held the shares for at least one year. Among the conditions for use of the Rule is the
availability of current information to the public about the Company. The undersigned understands that the Company has not made such information available and has no present plans to do so. 
 The undersigned further agrees not to make any disposition of all or any part of the shares being acquired in any event unless and until: 

 

	1.	The Company shall have received a letter secured by the undersigned from the Securities and Exchange Commission stating that no action will be recommended to the
Commission with respect to the proposed disposition; or 

  

			
		  	***Confidential Treatment Requested

	2.	There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with said registration
statement; or 

  

	3.	(i) The undersigned shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances
surrounding the proposed disposition, (ii) the undersigned shall have furnished the Company with an opinion of counsel for the undersigned to the effect that such disposition will not require registration of such shares under the Act, and
(iii) such opinion of counsel for the undersigned shall have been concurred in by the Company’s counsel and the Company shall have advised the undersigned of such concurrence. 

If requested by the Company and an underwriter of Common Stock (or other securities) of the Company, the undersigned shall not sell or otherwise transfer
or dispose of any Shares (or other securities) of the Company then owned by the undersigned (other than those included in such registration) during the one hundred eighty (180) day period (or such lessor period as is permitted by the
underwriter) following the effective date of a registration statement of the Company filed under the Act. 
 The undersigned
understands and agrees that all certificates evidencing the shares to be issued to the undersigned may bear the following legends: 
 “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.” 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST REFUSAL OPTION IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S), AS PROVIDED IN THE BYLAWS OF THE COMPANY.” 

Very truly yours, 
 THE
PENN STATE RESEARCH FOUNDATION 
  

			
	By:	 	 /s/ David E. Branigan

		
	Name:	 	 David E. Branigan

		
	Title:	 	 Treasurer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]